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The Association Of Patients' Analgesic Treatment Beliefs And Trade-Offs With 
Analgesic Adherence Behaviors Among Outpatients With Cancer Pain 
Abstract 
Pain is one of the most burdensome symptoms for patients with cancer. Per cancer pain guidelines, 
opioids remain one of the primary modalities for managing moderate to severe cancer pain. Analgesic 
nonadherence is common among cancer patients despite unmanaged pain symptoms. We investigated 
how patients prioritized analgesic treatment beliefs for cancer pain and whether those beliefs predicted 
objective analgesic adherence behaviors. 
This is a secondary analysis of an existing dataset (n=207) that used a three-month prospective 
observational design. Subjects were from outpatient oncology clinics of a large Philadelphia health 
system and were > 18 years, self-identified as African-American or White, diagnosed with solid tumor or 
multiple myeloma, and prescribed at least one around-the-clock analgesic for reported cancer pain. 
We conducted three studies to achieve the aims. First, we performed a concept analysis (Chapter 2) of 
analgesic nonadherence for cancer pain and qualified its utility in the context of the United States opioid 
epidemic. In Chapter 3, we used maximum difference scaling to identify how patients traded-off on 
analgesic treatment beliefs. Utilities (importance scores) were ranked using a k means cluster analysis; 
clusters were compared in terms of key variables. Finally, we employed general linear modeling to 
evaluate if analgesic belief clusters predicted analgesic adherence behaviors, assessed longitudinally 
using electronic medication monitoring while accounting for relevant confounders (Chapter 4). 
Initial results showed beliefs weigh significantly in subjective analgesic trade-offs. We identified two 
distinct belief clusters. Side effect severity was the only variable that significantly differed between 
clusters. Subjects mostly traded-off based on the belief, ‘pain medicines keep you from knowing what is 
going on in your body.’ Addiction was not a top priority. Belief clusters did not predict analgesic 
adherence. However, in an adjusted analysis, it was the experiential variables (e.g., side effects, most 
potent analgesia, pain relief with analgesics, duration of disease), as well as patients’ race, that were 
statistically significant in explaining analgesic adherence. 
Our findings suggest that experiential variables rather than analgesic beliefs were associated with 
analgesic adherence in this sample of cancer outpatients. Additional studies should explore patients’ 
cancer pain self-management practices while considering patient, provider, and system/ structural factors 
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THE ASSOCIATION OF PATIENTS’ ANALGESIC TREATMENT BELIEFS  
AND TRADE-OFFS WITH ANALGESIC ADHERENCE BEHAVIORS  
AMONG OUTPATIENTS WITH CANCER PAIN 
William E. Rosa 
Salimah H. Meghani 
Pain is one of the most burdensome symptoms for patients with cancer. Per cancer 
pain guidelines, opioids remain one of the primary modalities for managing moderate to 
severe cancer pain. Analgesic nonadherence is common among cancer patients despite 
unmanaged pain symptoms. We investigated how patients prioritized analgesic treatment 
beliefs for cancer pain and whether those beliefs predicted objective analgesic adherence 
behaviors.  
This is a secondary analysis of an existing dataset (n=207) that used a three-
month prospective observational design. Subjects were from outpatient oncology clinics 
of a large Philadelphia health system and were > 18 years, self-identified as African-
American or White, diagnosed with solid tumor or multiple myeloma, and prescribed at 
least one around-the-clock analgesic for reported cancer pain.  
We conducted three studies to achieve the aims. First, we performed a concept 
analysis (Chapter 2) of analgesic nonadherence for cancer pain and qualified its utility in 
the context of the United States opioid epidemic. In Chapter 3, we used maximum 
difference scaling to identify how patients traded-off on analgesic treatment beliefs. 
Utilities (importance scores) were ranked using a k means cluster analysis; clusters were 
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compared in terms of key variables. Finally, we employed general linear modeling to 
evaluate if analgesic belief clusters predicted analgesic adherence behaviors, assessed 
longitudinally using electronic medication monitoring while accounting for relevant 
confounders (Chapter 4).  
Initial results showed beliefs weigh significantly in subjective analgesic trade-
offs. We identified two distinct belief clusters. Side effect severity was the only variable 
that significantly differed between clusters. Subjects mostly traded-off based on the 
belief, ‘pain medicines keep you from knowing what is going on in your body.’ 
Addiction was not a top priority. Belief clusters did not predict analgesic adherence. 
However, in an adjusted analysis, it was the experiential variables (e.g., side effects, most 
potent analgesia, pain relief with analgesics, duration of disease), as well as patients’ 
race, that were statistically significant in explaining analgesic adherence. 
Our findings suggest that experiential variables rather than analgesic beliefs were 
associated with analgesic adherence in this sample of cancer outpatients. Additional 
studies should explore patients’ cancer pain self-management practices while considering 
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Pain has been identified as one of the most common experiences of the cancer 
trajectory (Shi et al., 2011). A recent systematic review and meta-analysis of 112 studies 
on pain (n=63,533) and pain severity (n=32,261) suggests an estimated two-thirds of 
patients with advanced or metastatic cancer report some pain, and up to 38% of patients 
report their pain as “moderate” or “severe” (van den Beuken-van Everdingen, 
Hochstenbach, Joosten, Tjan-Heijnen, & Janssen, 2016). Many patients with moderate to 
severe cancer pain require complex analgesic regimens, at times including a combination 
of nonopioids, short- and long-acting opioids, and adjuvant prescriptions to effectively 
mitigate pain and achieve an acceptable level of function and quality of life (National 
Comprehensive Cancer Network [NCCN], 2019; Paice et al., 2016; World Health 
Organization [WHO], 1986, 1996, 2018). Unfortunately, there is limited empirical cancer 
pain data available. The chronic pain literature often excludes patients with cancer from 
the very studies that inform pain management guidelines, drive policies, and establish 
prescribing standards for analgesics, including opioids (Meghani & Vapiwala, 2018).  
  Among the many challenges identified in managing cancer pain is patient 
deviation from prescribed analgesic regimens. This concept is known as “nonadherence”. 
Nonadherence to analgesics may complicate treatment plans and exacerbate symptoms 
among a population negatively impacted by cancer pain. Despite the prevalence of cancer 
pain, analgesic nonadherence persists and is poorly understood. A list of key terms 
relevant to the phenomenon of analgesic nonadherence and related concepts can be found 
in Table 1.  
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Analgesic nonadherence behaviors have a number of predictive and covarying 
factors. They may be influenced by an individual’s beliefs, preferences, and values 
(Gunnarsdottir, Donovan, Serlin, Voge, & Ward, 2002; Jacobsen et al., 2014; Liang et al., 
2013; Meghani & Knafl, 2017; Valeberg, Miaskowski, Paul, & Rustoen, 2016; Ward et 
al., 1993); patient and family caregiver hesitancy to use or support the use of analgesics 
(Lee et al., 2015; Valeberg et al., 2016); and sociodemographic considerations, such as 
race, socioeconomic status, and structural barriers, including insurance coverage (Bryan, 
De La Rosa, Hill, Amadio, & Wieder, 2008; Meghani et al., 2014; Meghani, Thompson, 
Chittams, Bruner, & Riegel, 2015; Valeberg et al., 2008; Wieder, Delarosa, Bryan, Hill, 
& Amadio, 2014) Current clinical interventions to decrease nonadherence rates have not 
achieved their aim. For example, Oldenmenger and colleagues reviewed 28 randomized 
controlled trials (n=4,735), showing patient education to reduce analgesic nonadherent 
behaviors are heterogenous and subpar at best, leading to a significant pain improvement 
outcome in less than 20% of all cancer pain patients (Oldenmenger et al., 2018). 
Additional studies are required to better inform tailored intervention strategies to 
individual and family needs in order to more thoroughly understand analgesic taking 
behaviors to prescribed treatment regimens and associated cancer pain burdens.  
Understanding Analgesic Nonadherence in the Context of the Opioid Epidemic 
 
Although many healthcare professionals would agree there is an ethical obligation 
to treat pain, that duty may be obviated by stigma and policy flux inherent to the opioid 
epidemic in the United States. The opioid crisis and its far-reaching implications are 
essential to understanding analgesic nonadherence for cancer pain. The crisis has 
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snowballed since the late 1990s (Centers for Disease Control and Prevention [CDC], 
2018; Kolodny et al., 2015) accompanied by avid disagreement regarding the future of 
pain assessment and ready access to opioid-related interventions. The debate over pain 
assessment and the priority of pain treatment using opioids is causing confusion and 
misunderstanding about the indication for opioids in mitigating cancer pain; impacting 
how patients take their analgesics and how providers prescribe them (American Pain 
Society Quality of Care Committee, 1995; Baker, 2017; Meghani & Vapiwala, 2018; 
Phillips, 2000; Rummans, Burton, & Dawson, 2018). Major leading reports recognize the 
complexities of managing cancer pain, the lack of longitudinal data required to fully 
understand the consequences of poorly managed pain, and the struggle of dual loyalties: 
reducing the individual burden of cancer pain while minimizing the mounting social 
sequelae of opioid use in America (National Academies of Sciences, 2017; National 
Academy of Medicine, 2017; National Institutes of Health, 2018). Given the rapidly 
changing landscape of opioid use in the setting of pain management, it is natural to 
assume that both patient and provider perceptions of opioid use will continue to evolve 
given ongoing policy and practice changes across settings and systems.  
Purpose and Innovation 
 
The purpose of this research is to explore the relationship between how patients 
prioritize their beliefs about analgesic treatment for cancer pain and their objective 
adherence behaviors. This purpose is achieved through a concept analysis of analgesic 
nonadherence for cancer pain and two research aims, discussed in greater detail in the 
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following sections. The anticipated findings will fill a critical gap in the literature related 
to how patient beliefs influence nonadherence rates.  
The trade-off methodology we will use, known as maximum difference scaling or 
‘MaxDiff’, is underutilized in the health care literature and may provide new insights 
regarding how patients prioritize their beliefs related to analgesic medication for cancer 
pain. While there has been some data reporting how patients make trade-offs related to 
analgesic treatment (Meghani, Chittams, Hanlon, & Curry, 2013), MaxDiff provides an 
innovative approach to identifying how patients trade-off on their decisions related to 
analgesic use. In addressing both research aims we will strive to first identify MaxDiff 
derived utilities (importance scores) and, second, we will determine if these utilities 
predict objective analgesic taking behaviors via an electronic medication monitoring 
system.  
Implications may inform how patient deviation from prescribed analgesics is 
addressed in the outpatient oncology setting and ways to individualize care based on 
patient priorities and beliefs, thereby improving adherence and subsequent patient, safety, 
and health outcomes in the future. Given the sample and study focus, this research is 
aligned with the NIH Minority Health and Health Disparities Strategic Plan and the 
NIH/NINR Strategic Plan’s Areas of Scientific Focus, including symptom science, self-





Parent Study and Sample Description 
 
This dissertation is based a secondary analysis of existing data (NIH/NINR RC1-
NR011591: PI Meghani, S.H.) The goal of the parent study was to explain racial and 
ethnic disparities in cancer pain outcomes, specifically to elicit trade-offs patients with 
cancer pain employ in making cancer pain treatment decisions and the relationship 
between patients' stated preferences (using Choice-based Conjoint analysis) and their 
adherence to scheduled analgesic treatment using the Medication Event Monitoring 
System (MEMS®) (Meghani, Chittams, Hanlon, & Curry, 2013; Meghani, Thompson, 
Chittams, Bruner, & Riegel, 2015). The parent study used a prospective observational 
design employing repeated measures at baseline (T1) and 3-month follow-up (T2). The 
parent study researchers were able to identify analgesic nonadherence as a predictor of 
hospitalization (Meghani & Knafl, 2016) and noted analgesic prescribing differences 
between African-American and White patients (Meghani et al., 2014). Parent study data 
was comprised of various sociodemographic, pain, and illness-related variables, and 
identified deviations from prescribed analgesic regimens among patients experiencing 
cancer pain in the outpatient oncology setting using multiple adherence measures at T1 
and T2. Additionally, patients’ chart data was collected for all subjects in the sample.  
Patients were recruited from two outpatient medical oncology services at the 
Hospital of the University of Pennsylvania in Philadelphia between December 2009 and 
August 2011. Inclusion criteria included patients 18 years or older who self-identified as 
White or African-American, were diagnosed with solid tumor (e.g., lung, breast, 
gastrointestinal, genitourinary/reproductive) or multiple myeloma, reported cancer pain, 
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and had at least one around-the-clock analgesic prescription. Patients receiving pain 
control through a transdermal system (e.g., Duragesic patch) were excluded. Once the 
research assistant verified that criteria eligibility were met, the patient’s oncologist 
verified eligibility.  
A sample of 241 subjects agreed to participate, were deemed eligible, and 
completed baseline assessments at T1. There was a 14% attrition rate over the three-
month period due to patient’s death, their being too sick to complete the study, refusal to 
participate, or loss to follow-up. Two hundred and seven subjects completed the study at 
T2. The sample for this dissertation (n=207) reflects the number of subjects who 
completed the parent study since both cross-sectional analysis at T1 and longitudinal 
methods involving T2 will be employed.  
Specific Aims and Respective Hypotheses 
 
Specific Aims of this dissertation are to:  
1. Clarify the concept of analgesic nonadherence for cancer pain and qualify its utility 
with respect to the United States opioid crisis. A conceptual definition of analgesic 
nonadherence will be identified through a rigorous synthesis of the literature for the 
purpose of parsimonious consistency in future use and application (Chapter 2).  
2. Elicit the trade-offs patients make about analgesic treatment for cancer pain based on 
their analgesic beliefs and concerns (Chapter 3).  




2b. Using utilities identified in 2a., conduct k means cluster analysis to identify 
distinct cluster membership among patients based on analgesic beliefs and 
concerns. 
2c. Describe cluster membership in 2b, by comparing key sociodemographic and 
clinical variables. 
Hypothesis: There will be unique subsets of cancer patients based on how they 
prioritize analgesic treatment beliefs for cancer pain and distinct differences between 
how patients prioritize their beliefs that will be decipherable among clusters.   
3. Explore whether the previously identified analgesic treatment belief clusters predict 
objective analgesic adherence over a three-month period as measured by an electronic 
medication monitoring system (MEMS®) while accounting for relevant confounders 
(Chapter 4).  
Hypothesis: Cluster membership based on analgesic treatment beliefs and concerns 
will predict differing levels of analgesic adherence. 
Chapter Synopsis 
 
This dissertation uses a “three-paper” format, as described below. 
Chapter 1 
Chapter 1 herein is an introduction and serves as an overview of analgesic 
adherence accompanied by relevant background information, specific aims, and 
descriptions of the current and parent study content. Details regarding human subjects, a 
9 
 
brief overview of methods, variables of interest and instrumentation, as well as the 
significance, innovation, strengths, and limitations, are provided.  
Chapter 2 
Chapter 2 addresses specific aim 1 and seeks to clarify the concept of analgesic 
nonadherence for cancer pain and qualify its utility in the context of the opioid crisis for 
patients, providers, researchers, and policy makers through an analysis of recent literature 
(Rosa, Riegel, Ulrich, & Meghani, 2020). Although the terms ‘analgesic adherence’ and 
‘analgesic nonadherence’ are used interchangeably throughout the literature, the way the 
concept is operationalized in research often waivers given the study at hand. A theoretical 
definition will be provided for the concept that will inform consistency in use and 
application in the future. In addition, a conceptual model is illustrated based on the 
individual-, provider-, and system-level antecedents and evidence-based consequences 
identified during analysis. Among other conclusions discussed in more detail in Chapter 
2, this author recognizes that the full impact of the role of analgesic nonadherence is yet 
to be determined. Figure 1 provides a conceptual model based on our analysis findings 
that serves as a theoretical premise for the remaining chapters.  
Brief Overview of Methods and Analysis  
Walker and Avant’s (2019) method of concept analysis is utilized to construct a 
precise conceptual definition of the phenomenon for future consistency in theoretical and 
empirical settings. Their method consists of the following steps: 1) selecting a concept; 2) 
determining the aims and purpose of the analysis; 3) identifying all discoverable uses of 
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the concept; 4) describing the concept’s defining attributes; 5) specifying antecedents and 
consequences; 6) articulating a model case; 7) identify related cases; and 8) defining 
empirical referents.  
 Chapter 3 Summary 
Specific aim 2 is to elicit the trade-offs patients make based on their beliefs about 
analgesic use and rank decision-making utilities using MaxDiff scaling and cluster 
analysis (Rosa, Chittams, Riegel, Ulrich, & Meghani, 2019). Specific aim 2 will be 
achieved using MaxDiff and k means clustering techniques through a cross-sectional 
analysis of baseline sample data at T1. Outcomes include descriptive findings that 
identify significant differences among how groups of subjects trade-off on analgesic 
treatment beliefs in relation to key sociodemographic and clinical variables.  
Brief Overview of Methods and Analysis  
MaxDiff is a discrete choice experiment that requires subjects to identify the 
‘least desirable’ preference related to a given attribute, as well as the ‘best’ or most 
preferred option available within a choice set (Finn & Louviere, 1992; Marley & 
Louviere, 2005). Thus, it is also known as “best-worst scaling” and is used to identify the 
maximum difference in preference between the “best” and “worst” choices available 
(Marley & Flynn, 2015). It boasts noted measurement advantages and distinct benefits in 
contrast with traditional survey techniques, conjoint analysis, and ranking methods, 
which may confuse study subjects with too many options in a given choice set and/or 
muddle findings in the absence of clear choice differences (Louviere, Flynn, & Carson, 
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2010; Marley & Flynn, 2015). Although MaxDiff has been traditionally used to identify 
consumer preferences among brands or items, the case has been made for its increased 
use in health care research (Flynn, Louviere, Peters, & Coast, 2007) as social sciences 
researchers are using it with greater frequency to better elicit patient preferences in a 
number of clinical settings (Feudtner et al., 2015; Louviere, Flynn, & Marley, 2015; 
Mooney-Doyle, Deatrick, Ulrich, Meghani, & Feudtner, 2018; October, Fisher, Feudtner, 
& Hinds, 2014).  
Subjects in this current study were instructed to select the statement that was 
“most” and “least” important to him or her in thinking about their pain medications in 
order to calculate the maximum difference between competing priorities (Figures 2 and 
3). The statements or ‘attributes’ provided to subjects in the parent study questionnaire 
were derived directly from the Barriers Questionnaire-II (Ward et al., 1993), a self-report 
instrument that evaluates varying aspects of how patients’ beliefs function as barriers to 
ideal cancer pain management. The theory undergirding MaxDiff and its application to 
this study is described with increased rigor in Chapter 3. The ten attributes assessed using 
MaxDiff in the parent study questionnaire can be found in Table 2 under the “Analgesic 
Preference” subheading.  
Once MaxDiff utilities based on analgesic treatment beliefs were identified, a 
cross-sectional cluster analysis of baseline data was performed to describe significant 
differences in preference patterns, and cluster membership was detailed in relation to key 
sociodemographic and clinical variables. Significant differences between the clusters 
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were assessed using chi-squared tests for categorical variables and analysis of variance 
(ANOVA) calculations for continuous variables.  
Chapter 4 
The goal of specific aim 3 is achieved in Chapter 4. Here, we explore whether the 
analgesic belief clusters identified through specific aim 2 predict objective analgesic use 
as measured by an electronic medication monitoring system while accounting for relevant 
confounders. This association was assessed based on analgesic treatment beliefs elicited 
at baseline (T1) and the objective analgesic adherence behaviors of patients measured at 
follow-up (T2).  
Brief Overview of Methods and Analysis  
General linear modeling using a backward elimination method will be used with 
the analgesic treatment belief clusters (T1) gathered in Chapter 3 functioning as an 
independent variable and predictor of objective analgesic adherence (T2 data). A number 
of clinically relevant confounders will be taken into consideration within the model, such 
as sociodemographic variables, level of social support, and analgesic side effects, to be 
discussed in depth in Chapter 4. The outcome variable in this longitudinal analysis will 
be objective adherence behaviors tracked with the Medication Event Monitoring System 
(MEMS®; Aardex, Switzerland) -  a well-established measure within the analgesic 
adherence literature (Meghani & Knafl, 2017; Meghani et al., 2015; Oldenmenger et al., 
2007; Oldenmenger, Sillevis Smitt, de Raaf, & van der Rijt, 2017). The MEMS® is 
recognized as the ‘Gold Standard’ for measuring adherence in academic research and has 
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demonstrated accuracy, ease with use, and patient acceptability, showing benefits in 
adherence measurement over numerous limitations associated with other methods (e.g., 
patient report, prescription refill data, biological measurement of medicine or metabolite 
levels) (Butler, Peveler, Roderick, Horne, & Mason, 2004; Farmer, 1999; Parker et al., 
2007; Puller, Kumar, Tindall, & Feely, 1989; Vrijens, Urquhart, & White, 2014).  
Chapter 5 
Chapter 5 will provide overall conclusions through an integrated discussion and 
synthesis of findings with implications for clinical practice, education, policy, and future 
research, as well as a summary of the major strengths and limitations of the dissertation.  
Study Variables, Measures, and Instrumentation 
 
 Analgesic Nonadherence. The actual rate of nonadherence is poorly understood 
and researchers must frequently negotiate the strengths and weaknesses of available 
metrics (Cleemput, Kesteloot, & De Geest, 2002). There are efforts underway to stratify 
reporting guidelines for medication adherence, which incorporate multidisciplinary 
perspectives, varying patient populations, and diverse geographical areas (De Geest et al., 
2018; Helmy et al., 2017). The measures of adherence in this current study include: 
• Medication Event Monitoring System (MEMS) is an objective metric of medication 
adherence through an electronic monitoring device technology (Aardex, Switzerland). 
MEMS uses a microprocessor chip implanted in a medication bottle cap to record 
the number of times the cap is removed in real-time. This data is subsequently 
recorded electronically and can later be analyzed as per the given protocol. The parent 
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study measured around-the-clock analgesic adherence as “dose adherence”, defined 
as the percentage of the total amount of prescribed doses taken. Methods for dose 
adherence calculations and a risk-reducing strategy to minimize the Hawthorne effect 
were published previously (Meghani et al., 2015).   
Pain-related Variables. A number of pain-related variables are used to assess 
pain and pain treatment, medication side-effects, barriers to optimal cancer pain 
management, and efficacy of prescribed analgesics based on reported pain severity. Pain-
related variables will be measured using: 
• Brief Pain Inventory (BPI-LF) provides a comprehensive evaluation of pain and pain 
treatment variables through using a 32-item self-report instrument (Cronbach’s alpha: 
0.77-0.91). Of interest, we will be using pain average and pain interference scores, 
which are measured on an 11-point scale. 
• Medication Side-effect Checklist (MSEC) is an 8-item scale that identifies the 
presence, as well as the type and severity of commonly occurring analgesic side 
effects (internal consistency: 0.81). Subjects are asked to rate severity of adverse 
effects in the preceding week on a scale of 0-10, with “0” being “no severity” and 
“10” being “extreme severity”.  
• Barriers Questionnaire (BQ-II) is a an 8-item revision of the original Barriers 
Questionnaire (Ward et al., 1993) that assesses a host of patient-reported cancer pain 
management barriers (subscale Cronbach’s alpha: 0.75-0.85, internal 
consistency=0.89). Four factors establish the construct validity for the BQ-II: (1) 
physiological effects (beliefs about side effects, tolerance concerns, other 
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considerations about being unable to identify bodily changes in the setting of strong 
pain medicine use); (2) fatalism (fatalistic beliefs about cancer pain and respective 
treatment); (3) communication (distracting physicians from a focus on disease 
management through pain reporting and the equivocation of a “good” or “strong” 
patient with not complaining about pain); and (4) harmful effects (fears of pain 
medication addiction and their subsequent damage to the immune system).  
• Pain Management Index (PMI) measures efficacy of a given analgesic prescription in 
relation to the reported degree of pain and is based on the analgesic ladder for cancer 
pain created by the WHO (1986, 1996). Insufficient pain management is generally 
reflected by a negative PMI score while an acceptably adequate analgesic prescription 
is indicated by a PMI score of 0 or greater. The PMI is calculated by initial 
identification of the analgesic “step” per the WHO cancer pain ladder (1986, 1996, 
2018): step 1 = non opioid (nonsteroidal anti-inflammatory agents, acetaminophen); 
step 2 = weak opioid (codeine, dihydrocodeine, tramadol, combination agents [e.g., 
oxycodone + acetaminophen]); step 3 = strong opioid (morphine, hydromorphone, 
synthetic opioids, Fentanyl). Level of pain is identified per the BPI-LF  “worst pain” 
rating on the previously described scale of 0-10. While more recent findings have 
questioned reliable implications of negative PMI scores, it continues to be a 
frequently used measure to evaluate adequacy of prescribed analgesic regimens in 
relation to patient-reported cancer pain (Deandrea, Montanari, Moja, & Apolone, 
2008; Sakakibara, Higashi, Yamashita, Yoshimoto, & Matoba, 2018). 
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 Demographic variables. The parent study questionnaire gathered information on 
a host of demographic variables (e.g., age, gender, self-identified race, marital status, 
education, computer literacy, income, health insurance, occupation, and status of 
employment), identified in detail in Table 2. Additional instruments related to health 
literacy and social support were used due to potential correlation with medication 
adherence, including: 
• Health Literacy Questions (HLQ) is a 3-item scale that has performed well against the 
standard health literacy measure, the Test of Functional Health Literacy in Adults 
(TOFHLA). The HLQ was used only at T1 of the parent study to assess inadequate 
health literacy and asks: 
 How often do you have someone help you read hospital materials? 
 How confident are you filling out medical forms by yourself? 
 How often do you have problems learning about your medical condition 
because of difficulty understanding written information?  
• Sarason’s Social Support Questionnaire (SSQ6) assesses two measures of social 
support in a 6-item scale (e.g. availability of social support [SSQ-N] and satisfaction 
with available social supports [SSQ-S]). The subscales (SSQ-N and SSQ-S) measure 
the number of social supports and satisfaction with each of the identified supports 
respectively (subscale internal consistency=0.9).  
 Illness-related Variables. Medical chart data from each patient’s record included: 
stage of cancer; time since cancer diagnosis; the number and types of prescribed 
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analgesic medications; past history of alcohol or substance abuse; presence of depression; 
and comorbidity score. 
 Table 2 provides a comprehensive list of variables to be used in the dissertation 
analyses, the level of data, and how they are operationalized in the data set.  
Human Subjects 
 
 The parent study was approved by the University of Pennsylvania Institutional 
Review Board prior to its execution and all human subjects gave informed consent at that 
time. All protected health data was deidentified prior to commencement of this secondary 
analysis with no reference to personally identifiable information that may be linked to 
research subjects. Therefore, this work does not meet the definition of “human subjects 
research” according to the US Department of Health and Human Services, Title 45 CFR 
46.102(f). The University of Pennsylvania deemed this dissertation study “exempt” on 
these grounds with no need for additional approval (correspondence on file).  
Strengths and Limitations  
 
 This research maintains a number of strengths. First, a substantial advantage of 
this dissertation is the utilization of a rare existing dataset that allows for longitudinal and 
objective analyses of analgesic and opioid adherence observed in the outpatient oncology 
setting (Meghani et al., 2015; Meghani & Knafl, 2017). In fact, to our knowledge this is 
the only dataset that accomplishes these measures in the United States, with one 
identifiable exception of a much smaller sample size (Wright et al., 2019).  Second, the 
sample is roughly 42% African American (African American [n=86]; White [n=121]), 
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representing the analgesic treatment beliefs of a traditionally underrepresented racial 
minority group. Findings may contribute to further advances in the field of cancer pain 
disparities, as well as symptom management disparities at the system level. Third, it 
contributes to closing the gap in better understanding the relationship between patient 
beliefs and objective adherence behaviors to inform improved interventions in the future. 
Last, as previously mentioned, it leverages MaxDiff analysis to provide the first 
application of the best-worst scaling method to the field of analgesic nonadherence as far 
as we are aware. 
 There are also several limitations to consider. First among these is the age of the 
data; collection was completed in August 2011. However, this time period occurred 
during the second wave of the opioid crisis (CDC, 2018) and so we contend that our 
findings carry relevant implications for the evolving scholarly and sociopolitical contexts 
related to opioids and the opioid addiction epidemic. Second, the sample is limited to 
self-identified African American and White patients and, therefore, it will be unable to 
address the potential inequities or diverse considerations related to additional racial, 
ethnic, or other minority groups who have been previously identified in the disparities 
literature (Institute of Medicine, 2003; Meghani, Byun, & Gallagher, 2012). Third, the 
parent study used convenience sampling to recruit from the outpatient oncology setting 
and does not address how beliefs inform nonadherence behaviors in the inpatient, acute, 
long-term, or rehabilitative settings. However, it is impossible to perform MEMS 
monitoring with a probability or population-based sample and would be difficult to 





 Cancer pain is a detrimental symptom that threatens the health, well-being, and 
overall function of affected patients. Although many patients are prescribed analgesic 
regimens to alleviate the pain-related experience and associated symptoms, they often 
deviate from these recommendations for a wide array of reasons. The literature has 
identified several individual/family, provider, and system level covariates of 
nonadherence. However, little is understood about how patient beliefs related to analgesic 
treatment issues inform their objective adherence behaviors. This study attempts to fill 
this gap by employing innovative trade-off methodology techniques to describe patient 
belief utilities and correlating them with analgesic adherence behaviors. Findings are 
particularly relevant given the current context of opioid crisis and the need for more 
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Table 1. Key Terms. 
• Analgesics: classified per the World Health Organization (1986, 1996, 2018) cancer 
pain ladder as follows:  
 Step 1: Nonopioids (e.g., nonsteroidal anti-inflammatories) 
 Step 2: Weak opioids (e.g., codeine, tramadol) 
 Step 3: Strong opioids (e.g., morphine, Fentanyl) 
• Adherence: the extent to which a person’s behavior (e.g., taking medication), 
corresponds with agreed recommendations from a health care provider (Sabate, 
2001); often used interchangeably in the literature with the terms ‘compliance’ and 
‘concordance’ 
• Analgesic nonadherence: a behavioral deviation from a prescribed analgesic regimen; 
“a heterogenous construct that lends itself to varied results and interpretations based 
on the measures used or dimensions studied” (Meghani & Bruner, 2013, p. e23); 
operationalized through a number of subjective and objective measures 
• Maximum differential scaling or ‘MaxDiff’: a type of discrete choice experiment that 
requires subjects to identify the ‘least desirable’ preference related to a given 
attribute, as well as the ‘best’ or ‘most preferred’ option available within a choice set 
(Finn & Louviere, 1992; Marley & Louviere, 2005); also known as “best-worst 
scaling” and used to identify the maximum difference in preference between the 




• Medication Event Monitoring System (MEMS): objective metric of medication 
adherence through an electronic monitoring device technology (Aardex, Switzerland); 
uses a microprocessor chip implanted in a medication bottle cap to record the number 
of times the cap is removed in real-time; has been used in several studies to track 
analgesic adherence where the bottle cap openings serve as a proxy for analgesic 
taking behavior and are analyzed in comparison to prescribed regimens (Meghani, 
Thompson, Chittams, Bruner, & Riegel, 2015; Oldenmenger et al., 2007; 

















Table 2. Variables, Level of Data, and Variable Operationalization.  
Variable Level of Data Operationalization 
 
Demographics 
Age Continuous Selected from range  
Gender Categorical 1=male 
2=female 









Self-identified Race Categorical  1=African American 
2=Caucasian 
Education/Years of Formal 
Schooling 
Categorical 1=no schooling  
2=elementary 
3=high school  
4=college/trade 
5=more than college 
Employment Status Categorical 1=full-time outside home  
2=part-time outside home  
3=full-time at home 
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Household Income Categorical 1=less than 10k  
2=b/w 20k and 30 k  
3=b/w 20k and 30k  
4=b/w 30k and 50k  
5=b/w 50k and 70k  
6=b/w 70k and 90k  
7=greater than 90k 





Health Literacy Score Continuous 3-15 
Social Support Amount Score Continuous 0-9 (number of people  
identified) 
Social Support Satisfaction 
Score 
Continuous 1-6 (6=most satisfied) 
 
Disease-Related 













Length of Time Since 
Learning of Diagnosis 
Continuous 1-120 (months) 
 
Pain-Related 
Experience of Pain Present 






Length of Pain Due to Present 
Disease of Cancer 
Continuous 1-120 (months) 
Average Pain in the Last 
Week 
Continuous 0 (no pain) – 10 (worst 
imaginable pain) 





Number of WHO Step 1 
Analgesics 
Continuous 0-4 (4 total medications 
possible) 
Number of WHO Step 2 
Analgesics 
Continuous 0-4 (4 total medications 
possible) 
Number of WHO Step 3 
Analgesics 
Continuous 0-4 (4 total medications 
possible) 
Total number of analgesics 
(excluding co-analgesics) 




Co-analgesics Continuous 0-4 (4 total medications 
possible) 
Pain Management Index Continuous -3 -> +3 (negative=inadequate 




MaxDiff: Cancer pain cannot 
be relieved with medications 
Continuous 0-100% 
MaxDiff: Many people with 
cancer get addicted to pain 
medicine. 
Continuous 0-100% 
MaxDiff: Pain medicine 
weakens the immune system. 
Continuous 0-100% 
MaxDiff: Pain medicine can 
keep you from knowing 
what’s going on in your body. 
Continuous 0-100% 
MaxDiff: It is important to be 
strong by not talking about 
pain. 
Continuous 0-100% 
MaxDiff: Pain medicine 
makes you say or do 
embarrassing things.  
Continuous 0-100% 
MaxDiff: If doctors have to 
deal with pain, they won’t 
concentrate on treating the 
cancer.  
Continuous 0-100% 
MaxDiff: It is easier to put up 
with pain than with the side 
effects that come from pain 
medicine.  
Continuous 0-100% 
MaxDiff: If you use pain 
medicine now, it won’t work 
as well if you need it later.  
Continuous 0-100% 
MaxDiff: If I talk about pain, 





Barriers Questionnaire Total 
Effects Score 
Continuous  27-162 
Medication Side Effects Score Continuous 8-78 







How Much Pain Medication 
Taken in the Past Month 
(VASdose) 
Continuous 1(0%) – 11(100%) 
 
Disease-Related (Other) 
Charlson Comorbidity Score Continuous 0-13 














Level of General Health 
 
Continuous 1(best) – 5(worst) 
Number of Days in the Last 30 
Days That Your Physical 
Health Was Not Good  
Continuous 0-30 (days) 
Number of Days in the Last 30 
Days That Your Mental 
Health Was Not Good 























Figure 1. Conceptual Model of Analgesic Nonadherence for Cancer Pain (Rosa, Riegel,  
Ulrich & Meghani, 2020). 
 
*This figure depicts the concept of analgesic nonadherence (center), as well as the 
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Background: Pain is one of the most common symptoms identified along the cancer 
trajectory. Among patients with moderate to severe cancer pain, nonadherence to 
prescribed analgesics may complicate treatment plans and exacerbate pain severity. 
Nonadherent behaviors are likely due to a number of individual/family, provider, and 
system level factors and may lead to negative pain-related outcomes. The purpose of this 
concept analysis is to clarify the concept of analgesic nonadherence or cancer pain and 
qualify its utility in the context of the opioid crisis.  
Method: Walker and Avant’s (2019) method for concept analysis was used. We 
integrated empirical evidence, relevant literature, and sociopolitical considerations realted 
to the opioid crisis to provide critical and timely analysis. Data were collected from a 
search of PubMed, CINAHL, PsychINFO, and Scopus. The search yielded 418 individual 
records. Empirical articles using quantitative and qualitative methodologies pertaining to 
analgesic nonadherence for cancer pain in adult outpatient settings, written in English, 
with an abstract, and published between 2010 and 2018 were considered. Other relevant 
literature sources were used if additional criteria were met. A total of 33 records were 
selected for detailed review.  
Findings: Few studies link analgesic nonadherence to patient outcomes highlighting a 
significant literature gap. Given the available evidence, a definitions for analgesic 




Discussion: The paucity of empirical data combined with the implications of the opioid 
crisis and conflicting pain management guidelines create uncertainty about the utility of 
analgesic nonadherence. The concept of analgesic nonadherence warrants further 
normative and empirical research to clarify the role of opioids and the meaning of 




















A Concept Analysis of Analgesic Nonadherence for Cancer Pain  
in a Time of Opioid Crisis 
Introduction 
 
According to the Centers for Disease Control and Prevention (CDC; 2018), an 
estimated 68% of the 70,200 drug overdose deaths in the United States (US) in 2017 
involved the use of an opioid. In fact, the number of drug overdose deaths that implicated 
opioids increased six-fold between 1999 and 2017 (CDC, 2018). In the current climate of 
the opioid addiction epidemic, various stakeholders are calling for tighter opioid access 
policies, more rigorous prescribing standards, and increasingly tailored patient and 
community education mechanisms (Christie et al., 2017; National Academies of Sciences 
[NAS], 2017; National Academy of Medicine, 2017). While there has been robust focus 
on clinician implications related to responsible opioid stewardship, we still lack clear 
empirical understanding about the factors that correlate with patients’ use of analgesics.   
Opioids remain a keystone of moderate to severe cancer pain management 
(National Comprehensive Cancer Network [NCCN], 2019; Paice et al., 2016; World 
Health Organization [WHO], 2018), despite discrepant pain management guidelines that 
complicate prescribing practices (Meghani & Vapiwala, 2018). According to these 
guidelines, many patients with moderate to severe cancer pain require complex analgesic 
regimens, at times including a combination of nonopioids, short- and long-acting opioids, 
and adjuvant prescriptions, to effectively alleviate pain and improve overall function. 
Even though such medication treatment plans are often warranted, many patients deviate 
from recommended analgesic regimens or stop taking them altogether.  
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Patient nonadherence to prescribed analgesics for cancer pain may compromise a 
number of pain-related, health, and safety outcomes (Lee et al., 2015; Manzano, Ziegler, 
& Bennett, 2014; Meghani & Knafl, 2016). Cancer patients demonstrate nonadherent 
behaviors for a variety of reasons, ranging from individual and family factors (Lee et al., 
2015; Meghani & Bruner, 2013; Meghani, Chittams, Hanlon, & Curry, 2013; Meghani & 
Knafl, 2017) to provider and system level barriers (Bryan, De La Rosa, Hill, Amadio, & 
Wieder, 2008; Schumacher et al., 2014a; Wieder, Delarosa, Bryan, Hill, & Amadio, 
2014; Xu, Luckett, Wang, Lovell, & Phillips, 2018). 
The purpose of this concept analysis is to clarify the meaning of analgesic 
nonadherence for cancer pain and its use in the literature with respect to the US opioid 
crisis. We employ the Walker and Avant (2019) method to deconstruct this concept and 
articulate future implications for practice, research, education, and policy. To these 
authors’ knowledge, this is the first conceptual analysis of nonadherence specific to 
analgesics for cancer pain. A clearer understanding of analgesic nonadherence is crucial 
in order to streamline pain management plans and best assist patients in effectively 
mitigating their cancer pain burdens in the future.  
Background and Significance 
 
The Pain Experience 
Pain is a burdensome symptom affecting patients across the cancer trajectory. A 
recent systematic review and meta-analysis of 112 studies on pain (n=63,533) and pain 
severity (n=32,261) suggests an estimated two-thirds of patients with advanced cancer 
report “some” pain, and up to 38% of patients report their pain as “moderate” or “severe” 
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(van den Beuken-van Everdingen, Hochstenbach, Joosten, Tjan-Heijnen, & Janssen, 
2016). In a longitudinal study exploring cancer survivors’ symptom burden at one-year 
postdiagnosis (n=4,903), Shi and colleagues (2011) noted that pain was rated as one of 
the top three symptoms negatively impacting health-related quality of life. The authors of 
several literature syntheses and landmark reports conclude that cancer pain control may 
be suboptimal for many populations and call for enhanced mechanisms to improve 
equitable access and delivery of pain care services (Institute of Medicine [IOM], 2003; 
Meghani, Byun, & Gallagher, 2012; NAS, 2017; Xu et al., 2018). 
Analgesic Use 
A number of factors influence analgesic use. Individual beliefs, preferences, and 
values are likely to inform nonadherent behaviors. For instance, patients’ beliefs about 
analgesics may act as barriers to adherence, such as worries that these medications will 
cause physiological or immune system harm or will lead to addiction (Liang, Tung, et al., 
2013; Simone, Vapiwala, Hampshire, & Metz, 2012; Ward et al., 1993). Patient affective 
factors, such as emotional distress or anxiety, have been shown to correlate with 
nonadherence choices (Jacobsen et al., 2014). In addition to patients, their families and 
caregivers also play a significant role in determining analgesic use and the level of 
demonstrated adherence (Valeberg, Miaskowski, Paul, & Rustoen, 2016). In fact, distinct 
family dynamics and family member hesitancy to use analgesics may mediate patient 
adherence behaviors (Lee et al., 2015; Schumacher et al., 2014). The evidence points to 
several other considerations required to grasp the full breadth of the concept, such as the 
quality of clinician-patient communication and analgesic accessibility (Thinh et al., 
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2018). Other elements include socioeconomic status and structural barriers, including 
insurance coverage (Bryan et al., 2008; Valeberg et al., 2008; Wieder et al., 2014).  
The Sociopolitical Milieu 
The opioid crisis compounds the phenomenon of analgesic taking behaviors 
throughout the national healthcare system. Across the United States, opioid-related events 
led to a 64.1% increase of inpatient hospital stays and a 99.4% increase in emergency 
department visits between 2005 and 2014 (Rudd, Seth, David, & Scholl, 2016); and in 
2015, opioid-related deaths led to overall economic costs estimated at $504 billion or 
roughly 2.8% of gross domestic product (The Council of Economic Advisors, 2017). The 
crisis marks an era of policy flux, rigorous scientific debate, and multi-agency 
collaboration to balance the dual loyalties of reducing the individual burden of cancer 
pain while minimizing the mounting social sequelae of opioid use in America (Johnson et 
al., 2018; Lamar, 2018; NAS, 2017; National Institutes of Health [NIH], 2018; US 
Department of Health and Human Services, 2017). An additional complicating feature is 
the recent identification of the critical divide between cancer pain management guidelines 
of leading pain organizations (Meghani & Vapiwala, 2018). These inconsistent standards 
are  due to the daunting lack of accumulated empirical evidence related to cancer pain 
management (Meghani & Vapiwala, 2018; NIH, 2014). The concept of analgesic 
nonadherence is likely to be best understood by accounting for both the context of the 







 Walker and Avant’s (2019) approach to concept analysis (Box 1) is employed to 
construct a precise conceptual definition of analgesic nonadherence for cancer pain for 
future theoretical and empirical consistency. This method was selected due to its 
inclusion of example cases, offering a pragmatic application of the conceptual aspects, 
which is essential given the sociopolitical background previously mentioned. 
Additionally, this method stresses an iterative approach, promoting continuous 
exploration and clarification throughout the process. Finally, since concepts are tentative 
in nature, it is crucial to be aware of the cultural, contextual, and social factors that 
contribute to the current understanding of the concept at hand (Walker & Avant, 2019). 
Therefore, this method allows the reader to relate analysis findings directly to the health 
and policy dynamics of the US opioid crisis.  
The initial search in PubMed used the MeSH search (‘neoplasms’ OR ‘cancer’ 
OR ‘cancer pain’ OR ‘cancer related pain’) AND (‘treatment adherence and compliance’ 
OR ‘medication adherence’ OR ‘patient compliance’) AND (‘analgesics’ OR ‘analgesics, 
opioids’ OR ‘narcotics’). Further searches in CINAHL, PsycINFO, and Scopus used the 
above terms as keywords. Search terms were defined in collaboration with a librarian at 
the University of Pennsylvania Biomedical Library, Philadelphia, Pennsylvania. The 
search yielded 418 individual records; duplicates, articles in languages other than 
English, and those without an abstract were excluded. Empirical articles using 
quantitative and qualitative methodologies and pertaining to analgesic nonadherence for 
cancer pain in adult inpatient and outpatient settings, written in English, with an abstract, 
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and published between 2010 and 2018 were considered.  This time period was chosen 
because it spans the current opioid crisis in the United States according to related 
literature that emerged during its peak in 2010.  
Relevant internationally gathered evidence was employed if it contributed distinct 
considerations regarding the concept not addressed in US-based literature. Organizational 
pain management guidelines and recommendations, as well as seminal documents outside 
of the proposed time frame that continue to influence current analgesic policy and 
practice were included.  Non-empirical sources included records from Merriam Webster 
dictionary (n=2); WHO (n=3); NCCN (n=1); and previous related concept analyses 
(n=2). After applying exclusion criteria (Figure 1), a total of 33 records were selected for 
detailed review.  
Results 
 
Uses of the Concept 
 The terms adherence and nonadherence are often used interchangeably in the 
literature and are facets of the same phenomenon. Other terms such as noncompliance 
and nonconcordance have been employed synonymously with nonadherence. The 
Merriam-Webster dictionary defines nonadherence as “a lack of adherence” (Merriam-
Webster, n.d.-b). It is, therefore, essential to grasp the meaning of adherence. Adherence 
is “the act, action or quality of adhering” or “steady or faithful attachment” (Merriam-
Webster, n.d.-a). Previous concept analyses of adherence define it as a “complex, 
multidimensional concept impacted by essential elements such as autonomy, self-
determination, self-efficacy, and communication” (Gardner, 2015, p. 100). Other authors 
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emphasize the concept should be considered through a patient-centered lens, 
incorporating an individual’s context in how it is evaluated (Alikari & Zyga, 2014). The 
WHO (2003) identifies patients’ active participation in medical plan development as a 
primary factor that differentiates adherence from the historical notion of compliance. The 
WHO (2003) defines adherence as “the extent to which a person’s behavior – taking 
medication, … executing lifestyle changes, corresponds with agreed recommendations 
from a health care provider” (p. 3).  
Analgesics are classified using the WHO (1986, 1996, 2018) cancer pain ladder 
and includes step 1 - nonopioids (e.g., nonsteroidal anti-inflammatories); step 2 - weak 
opioids (e.g., codeine, tramadol); and step 3 – strong opioids (e.g., morphine, Fentanyl). 
Opioids are further classified as long-acting, used to obtain background analgesia for 
chronic cancer pain, and immediate-release, taken to treat breakthrough pain and deliver 
a quicker onset but shorter duration of pain relief (NCCN, 2019). Some studies include a 
patient’s use of coanalgesics, such as antidepressants, anticonvulsants, or corticosteroids, 
in understanding predictors of overall nonadherence to pain management 
recommendations (Schumacher et al., 2014b). Researchers may focus on adherence 
related to one particular step of the cancer pain ladder, such as strong opioids 
(Chancellor, Martin, Liedgens, Baker, & Muller-Schwefe, 2012); assess differences in 
rates of adherence between nonopioids and opioids (Oldenmenger et al., 2017); focus 
primarily on short- or long-acting opioids (Yoong et al., 2013); or include a broad range 
of analgesic types (Simone et al., 2012).  
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Analgesic nonadherence has been recognized as “a heterogenous construct that 
lends itself to varied results and interpretations based on the measures used or dimensions 
studied” (Meghani & Bruner, 2013, p. e23). How analgesic nonadherence is empirically 
represented varies. For example, some studies define analgesic nonadherence using 
subject self-report (Meghani & Bruner, 2013); computed rates of adherence based on 
proportions of prescribed doses taken during a given time period (Meghani, Thompson, 
Chittams, Bruner, & Riegel, 2015; Rhee et al., 2012); or the number of patients found to 
be taking medications as recommended during follow-up appointments (Wieder et al., 
2014). Other researchers study the proportion of doses taken correctly across a given 
number of days and within given time intervals per day in relation to medical 
recommendations (Oldenmenger et al., 2017) or the amount of opioid taken in 
comparison to the amount of opioid prescribed (Nguyen et al., 2013).  
Defining Attributes  
Attributes are the qualities or features most commonly associated with a concept 
(Walker & Avant, 2019). The primary defining attribute of analgesic nonadherence is a 
behavior that establishes deviation from a prescribed regimen and may be the result of 
both conscious and unconscious influences (Meghani & Bruner, 2013; WHO, 2003). 
Such behaviors include filling prescriptions, taking medications as prescribed, attending 
scheduled appointments, adopting health behavior change, etc. (WHO, 2003). These 
behaviors have been identified as intentional, unintentional, and/or temporal. Intentional 
nonadherence is a deliberate choice not to follow a given recommendation; an active 
decision reflects a patient’s desire to stop taking their analgesic (Morisky, Green, & 
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Levine, 1986). Unintentional nonadherence is an unconscious, relatively passive process 
that results in similarly noted behavior (Morisky et al., 1986). Temporality is an 
important attribute (Meghani & Knafl, 2016). While some nonadherent behaviors were 
found to be habitual, many were influenced by temporal choices and priorities, 
fluctuating in accordance with changes to patients’ daily, weekly, or monthly schedules 
(Manzano et al., 2014). 
Antecedents of Analgesic Nonadherence  
 Per Walker and Avant (2019), antecedents are events that must be in place prior 
to the occurrence of the concept whereas consequences reflect the outcomes of the 
concept. For clarity, antecedents have been categorized as individual/family level, 
provider level, and system level.  
Individual/family level. Identifying patients’ main anchors for decision-making is 
central to understanding the driving forces of nonadherent behaviors. In a study of 207 
outpatient oncology subjects, about 41% maintained an expectation of pain relief that 
primarily determined analgesic decision-making; 11% were most concerned with the type 
of analgesic used; roughly 28% were driven by multifactorial determinants including pain 
relief and the type and severity of side-effects; and 21% were influenced predominantly 
by the type of side effects experienced (Meghani & Knafl, 2017). Longitudinal 
qualitative findings echo that the extent to which side effects interfere with a patient’s life 
directly coincides with nonadherence behaviors (Manzano et al., 2014). Researchers 
using a phenomenological method to elicit the illness narratives of cancer patients (n=18) 
suggested that self-perceived benefits of following an analgesic regimen, subjective self-
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efficacy, and trust in healthcare providers improved adherence; denial of pain as a 
symptom of the disease process posed a barrier (Torresan et al., 2015). 
Such concerns, in addition to beliefs and preferences have been well-documented 
predictors of nonadherent behavior to analgesic regimens, particularly to opioids 
(Chancellor et al., 2012; Rhee et al., 2012). This includes patients’ concerns about the 
physiological effects of opioids and worry about dependence or addiction (Jacobsen et 
al., 2014; Liang, Chen, et al., 2013; Simone et al., 2012), as well as a belief that doctors 
should focus on cancer treatment rather than pain (Rhee et al., 2012). Families and 
caregivers play a pivotal role in this phenomenon. Family hesitancy to use analgesics has 
been found to mediate patients’ barriers and patients’ adherence (Lee et al., 2015). 
Furthermore, family characteristics directly impact the home environment in which 
patients live and anchor their analgesic decision-making processes (Schumacher et al., 
2014b). 
Various sociodemographic variables have been identified to play a predictive role 
in opioid nonadherence. Studies disagree whether males or females demonstrate 
nonadherent behaviors more frequently (Liang, Wu, Tsay, Wang, & Tung, 2013; Liang, 
Wang, et al., 2013; Nguyen et al., 2013). The same empirical variation occurs in 
reference to age, with some investigators noting increased nonadherence among younger 
cancer patients (Koyyalagunta et al., 2018); however, older patients may be more likely 
to intentionally stop taking medications when they feel better (Meghani & Bruner, 2013). 
Other predictors, including income, education and health literacy levels, and level of 
prescription coverage have been identified as significant (Meghani & Knafl, 2017; 
54 
 
Wieder et al., 2014). It appears challenging for patients to take scheduled analgesics at 
the correct time intervals due to scheduling issues, forgetfulness, and the complexities of 
daily life (Oldenmenger et al., 2017). Of note, increased use of complementary and 
alternative medicine for cancer pain management was positively correlated with 
unintentional nonadherence (Meghani & Bruner, 2013). 
Perhaps one of the most glaring sociodemographic antecedents is race - even 
when controlling for insurance and socioeconomic status (IOM, 2003). African-
Americans are found to experience increased severity of pain more frequently than White 
counterparts (Martinez, Snyder, Malin, & Dy, 2014). Additional studies have shown that 
African-Americans are more likely to make nonadherence choices based on the “type of 
side effects” experienced rather than “pain relief” (Meghani et al., 2013; Meghani & 
Knafl, 2017), which means nonadherence may be more common in African-American 
patients due to a higher rate of side effects from inappropriately prescribed analgesics 
(Meghani et al., 2014). 
Provider Level. Prescribing practices are a major aspect of provider level 
antecedents. Patients prescribed around-the-clock (ATC) analgesics other than long-
acting opioids were more inconsistently adherent (Meghani & Knafl, 2016). Racial 
disparity is also a factor at the provider level. African-Americans may receive 
inconsistent or erroneous pain assessments by healthcare providers (Wandner et al., 
2014) and are less likely to be prescribed long-acting opioids for pain relief (Meghani et 
al., 2015). Meghani et al. (2014) suggest race is a strong predictor of both the type of 
opioid prescribed and the severity of analgesic side effects incurred. For example, 
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African-Americans have 71% lower odds than Whites of being prescribed oxycodone 
versus morphine in the setting of chronic kidney disease (CKD) (Meghani et al., 2014). 
This is crucial as morphine accumulates toxic renal metabolites in the setting of CKD that 
exacerbate negative side effects and may promote nonadherence. Other minorities, such 
as Hispanic patients, have also been noted to be prescribed fewer long-acting opioids than 
Whites (Meghani et al., 2015; Wieder et al., 2014). 
System Level. Researchers’ interviews with cancer patients (n=42) and family 
caregivers (n=20) point to a number of system level antecedents, including complex 
clinical care, reimbursement, and analgesic regulation processes; obtaining analgesics; 
and the patient/family burden of coordinating care and assuring effective communication 
among different providers (Schumacher et al., 2014a). Insurance and prescription 
coverage is a substantive predictive factor, with less coverage often afforded racial and 
ethnic minorities  (Wieder et al., 2014). 
Consequences of Analgesic Nonadherence 
There are notably few studies that actually link nonadherence to patient or health 
utilization outcomes. This is a significant gap in the literature. Notwithstanding, the 
consequences identified impact myriad life domains. In a cross-sectional and descriptive 
study of 176 patient-caregiver dyads, patients with lower adherence levels who lived in 
settings where families were hesitant to use analgesics reported an increased severity of 
pain (Lee et al., 2015). Among a sample of 196 outpatient oncology subjects taking 
around-the-clock analgesics in a three-month prospective observational study, an 
interaction of strong (WHO step 3) opioids and inconsistent adherence was the strongest 
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predictor of hospitalization (Meghani & Knafl, 2016). Finally, researchers using an 
exploratory longitudinal design and qualitative research methods found that patients 
(n=11) who experienced increased pain secondary to analgesic nonadherence sustained 
negative impacts to both physical and social functioning, as well as overall quality of life 
(Manzano et al., 2014).  
Model Case 
Take the case of a 40-year-old male diagnosed with stage III colon cancer. He is 
prescribed long-acting oxycontin 20mg by mouth twice daily and oxycodone 5-10 mg by 
mouth every 4 hours as needed for breakthrough spinal pain due to metastatic disease. He 
is terrified of becoming addicted to opioids despite no relevant family or personal history 
and he consistently chooses to forego his oxycontin. The patient will take his oxycodone 
only when his pain is unbearable. His wife is also adamant he not take opioids due to the 
news of the national crisis and fear her husband may suffer an overdose. His current 
prescriber insists on him following the regimen as recommended and provides 
standardized education in the form of a brochure intended to alleviate his worries. Of 
note, this is his first time seeing a pain specialist. His oncologist did not think opioids 
were indicated and suggested nonopioid analgesics to manage the patient’s cancer pain 
since he is not currently receiving active cancer treatment. This patient’s intentional 
nonadherence has led to multiple emergency room visits for pain crises and a rapid 
deterioration of quality of life since he is unable to eat, sleep, or work secondary to 
uncontrolled pain.  
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This case reflects the ways a patients’ salient concerns, family hesitancy, 
prescribers’ lack of clarity regarding guidelines, and depersonalized education intersect to 
impact a patient’s nonadherence behaviors (Lee et al., 2015; Meghani & Knafl, 2017; 
Meghani & Vapiwala, 2018) and subsequent increase in healthcare utilization (Meghani 
& Knafl, 2016). Additional cases might describe other challenges, such as analgesic 
access given insurance coverage gaps, ineffective coordination between healthcare 
services, or how race has been shown to predict nonadherence (Meghani et al., 2014; 
Schumacher et al., 2014a; Wieder et al., 2014).  
Related Case 
According to Walker and Avant (2019), a related case may depict some of the 
attributes of a concept but also differs from them when examined more closely; a 
particularly relevant approach to this phenomenon. Take the case of a 34-year-old 
undomiciled African-American woman recently discharged from a public urban hospital 
for uncontrolled pain secondary to her advanced breast cancer. Her primary insurance is 
Medicaid. She experienced confusion and nausea to inpatient trials of morphine and then 
oxycodone for pain control, finally achieving a desirable response to Fentanyl. While 
admitted to the hospital, she felt her pain was being inappropriately managed and 
inconsistently assessed. In addition, she has CKD and had been resistant to taking 
morphine for this reason. She is ultimately discharged with prescriptions for a 100 
microgram/hour transdermal Fentanyl patch to be changed every 72 hours and 
hydromorphone 8-12mg by mouth every 3 hours as needed for breakthrough pain. She 
denies side effects and endorses tolerable pain on this regimen. After discharge, she is 
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told by the local pharmacist that Medicaid will not pay the cost of her prescriptions and 
she must use a cheaper medication, such as morphine. The licensed independent 
practitioner at her oncologist’s office writes the new prescription that Medicaid will 
cover. The patient uses her remaining Fentanyl and hydromorphone, foregoes taking the 
morphine due to the adverse effects she previously experienced, and ends up in the 
emergency room later that week in a pain crisis. It takes an additional week to gain 
insurance approval for the analgesic regimen that works best for her to ensure a safe 
discharge – a structural barrier that prevents adherence to the regimen as prescribed.  
System-wide challenges, such as analgesic access given insurance coverage issues 
and ineffective coordination between prescribers and various healthcare services, makes 
adherence impossible (Schumacher et al., 2014a; Wieder et al., 2014). This case also 
illustrates how race has been shown to predict nonadherence based on the inappropriate 
use of opioids and inaccurate assessment of pain (Meghani et al., 2014). 
Empirical Referents 
 Empirical referents are the means through which the concept can be recognized 
and its defining attributes measured (Walker & Avant, 2019). Assessing the underlying 
factors that influence nonadherence and determining their basis is essential. For example, 
eliciting intentional versus unintentional processes that result in nonadherent behavior 
have suggested distinct correlates and decision-making heuristics for each category 
(Meghani & Bruner, 2013; Morisky et al., 1986). Objective measures used in the 
analgesic adherence literature include the use of an electronic medication event 
monitoring system, a tool that records the number of analgesic bottle openings as a proxy 
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for adherence, subsequently correlating findings with prescribed analgesic frequency 
(Meghani et al., 2015; Oldenmenger et al., 2017).  
Incorporating self-reported levels of adherence may capture a key element in 
unraveling how nonadherence presents in the cancer pain setting. It has been noted that 
subjective analgesic-related beliefs poorly explain objective analgesic taking, which is 
influenced more strongly by clinical pain variables (e.g., severity of adverse effects, pain 
relief, etc.) (Meghani & Knafl, 2016; Meghani et al., 2015). However, subjective 
measures may be helpful to understand medication-taking habits, comparing objective 
data to self-reported adherence for increased validity of findings, and recognizing the 
various preferences and behaviors that interact to result in nonadherence (Meghani et al., 
2013; Meghani & Knafl, 2017)  
Figure 2 provides a model to depict this concept’s defining attributes, antecedents 
and consequences, and empirical referents. 
Discussion 
 
  This analysis has sought to clarify the concept of analgesic nonadherence for 
cancer pain and its use in the literature given the current sociopolitical implications of the 
opioid crisis. In sum, the literature falls short, leaving us with more questions than 
answers. Only a handful of studies have made the link between analgesic nonadherence 
and outcomes, which include increased pain severity, higher rates of hospitalization, and 
decreased overall quality of life (Lee et al., 2015; Manzano et al., 2014; Meghani et al., 
2014; Meghani & Knafl, 2016). Ultimately, ‘what’ defines optimum adherence behavior 
is not clear. This paucity of evidence combined with the practice and policy shifts 
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resultant of the opioid crisis invite a new commitment to further empirical studies in this 
area. Based on this analysis - while also considering the implications of the current 
national context - a more inclusive definition of analgesic nonadherence for cancer pain 
is posed: Patient deviation from a prescribed analgesic regimen for cancer pain, 
predicted by highly contextual factors within individual/family and societal domains and 
potentially complicating both one’s symptom burden and a variety of health outcomes.  
There is insufficient reliable evidence to denote a value judgment on analgesic 
nonadherence as “good” or “bad”. However, initiatives and policies aimed at mitigating 
the crisis are complicating patient access, decreasing the willingness of prescribers to 
give opioids, and limiting prescription coverage for patients requiring analgesics, 
ultimately impacting patients’ use (Johnson et al., 2018; Lamar, 2018; NAS, 2017). The 
question of how to balance social welfare while upholding the moral obligation to 
alleviate pain and suffering is at the center of this crisis (NAS, 2017), as well as inherent 
to the antecedents of analgesic nonadherence faced by patients.  
 Current cancer pain management guidelines are limited by a dearth of empirical 
research on long-term opioid use to support best practices; the result is conflicting 
recommendations from a number of organizations (Meghani & Vapiwala, 2018; 
Ranapurwala, Naumann, Austin, Dasgupta, & Marshall, 2019). Although many 
guidelines identify opioids as foundational to effective relief for moderate to severe 
cancer pain (NCCN, 2019; Paice et al., 2016; WHO, 2018), the CDC discourages opioid 
use as a first-line treatment for cancer survivors, who are likely to continue to experience 
pain long after active cancer treatment has concluded (Dowell, Haegerich, & Chou, 2016; 
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Shi et al., 2011). These competing guidelines are likely to cause confusion among 
clinicians, placing patients at risk for subpar, ineffective, and/or risky consequences 
(Meghani & Vapiwala, 2018). In understanding analgesic nonadherence, we must ask: 
Adherence toward what end? Adherence based on which guidelines and considering what 
literature?  
Specifically, Meghani and Vapiwala (2018) point out conflicting 
recommendations regarding the use of long-acting and immediate-release opioids, which 
may also affect adherence behaviors. For instance, they point out that per the NCCN 
(2019), long-acting opioids to provide background analgesia should be used in 
combination with immediate-release opioids for breakthrough pain; however, the CDC 
(Dowell et al., 2016) discourages long-acting opioid use, particularly when immediate-
release opioids are concurrently prescribed. A crucial question is: What does analgesic 
nonadherence mean in the context of the CDC opioid guidelines, particularly in the 
absence of empirical data for this patient population? In other words, how do providers 
ensure timely, effective pain management by addressing adherence concerns for cancer 
patients at risk for poor pain control, especially in settings that employ inappropriately 
applied guidelines for the population at hand?  
The continued study of analgesic nonadherent behaviors in the cancer pain field 
given guideline discrepancies and emergent policy debates will be essential to improve 
care for affected patients. Furthermore, several studies focus specifically on adherence to 
ATC pain regimens (Meghani & Knafl, 2016; Yoong et al., 2013); which may warrant 
distinct considerations from those patients prescribed only immediate release analgesics. 
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In the trend toward prescribing fewer long-acting scheduled analgesics and using 
primarily immediate release medications, the concept of analgesic nonadherence and its 
consequences becomes vastly unclear. This paradox requires further investigation to 
determine similarities and differences between adherence to both long-acting and 
immediate release analgesics. . 
Patients’ nonadherent behaviors have been observed in the literature using various 
patient-reported surveys and instruments and technologies (Meghani & Bruner, 2013; 
Meghani et al., 2013), which makes it difficult to understand and explicate nonadherence 
and underlying decision-making processes across studies. Further exploration is needed 
to test the interplay of objective and subjective nonadherence measures, as well as 
qualitative data that seeks to tease apart the underlying patterns that result in nonadherent 
behavior. Additional research might further explore how analgesic adherence choices are 
made and the utilities and tradeoffs employed by patients in the decision-making process. 
Tailored education for patients, families, and prescribers regarding safe and 
effective analgesic use may assist in promoting that the holistic determinants of 
nonadherence are addressed. This requires attention to patient-centric models that elicit 
individual preferences and values, mitigate risks, and empower prescribers to correctly 
apply guidelines. Oldenmenger and colleagues (2018) systematically reviewed 28 
randomized controlled trials (n=4,735), showing that standard patient education programs 
to reduce analgesic nonadherence may be effective but are correlated with a significant 
pain improvement outcome in less than 20% of all cancer pain patients. These results 
highlight additional research gaps in this area.  
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Overall imperatives include the improvement of pain control, function, and 
quality of life and ultimately determining if heightened scholarly focus on nonadherence 
has a meaningful role in meeting these outcomes. Furthermore, available evidence is 
inconclusive about how to best decrease nonadherent behaviors and understand its role in 
predicting patient outcomes.  
Limitations 
 
 The findings of this concept analysis should be considered in light of the 
following limitations. While MeSH terms were used, the diversity of terms chosen to 
describe nonadherent behavior may have resulted in the omission of some articles during 
the literature review. Though a limited number of organizational recommendations prior 
to 2010 were included in the analysis due to their continued influence on analgesic 
management of cancer pain and adherence, the selected time frame of the search criteria 
(2010-2018) may have overtly limited additional meaningful records for this 
phenomenon which possesses an already extensive literature gap. While this analysis was 
approached with consideration to the US opioid crisis, broader inclusion criteria in the 
future might invite a different understanding of the concept when explored through the 
lens of opioid use and availability in the international arena and across diverse cultures. 
Conclusion 
 
 Cancer pain impacts patients and families by limiting physical and social 
function, negatively impacting quality of life, and complicating already taxing oncology 
treatment plans. Analgesic nonadherence in the current sociopolitical milieu deserves 
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further scholarly dialogue and research to further elicit its relationship to cancer pain; in 
short, the role of nonadherence in shaping clinical outcomes must continue to be 
addressed. Ultimately, a more detailed understanding of the physiological mechanisms of 
analgesic nonadherence may lead to interventions at individual and aggregate levels that 
support patients in employing pain medication regimens to more effectively meet their 
needs. 
It is impossible to sever the complexities related to the opioid crisis from factors 
that influence analgesic nonadherence. In fact, the opioid crisis is a crucial and 
underexplored antecedent of analgesic nonadherence. The context that birthed the 
addiction epidemic, including the beliefs, preferences, and values of both providers and 
patients, continues to evolve in an era of stigma and policy fluctuation. The full impact of 
the role analgesic nonadherence plays in cancer pain management, particularly within this 
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Box 1. Concept Analysis Process (adapted from Walker & Avant, 2019). 
1. Select a concept. 
2. Determine analysis aims and purpose.  
3. Identify all discoverable uses of the concept. 
4. Describe the concept’s defining attributes. 
5. Specify antecedents and consequences of the concept.  
6. Articulate a model case. 
7. Identify a related case. 





















Figure 2. Conceptual Model of Analgesic Nonadherence for Cancer Pain (Rosa, Riegel,    




*This figure depicts the concept of analgesic nonadherence (center), as well as the 













Patient Trade-Offs Related to Analgesic Use for Cancer Pain:  
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Purpose: Many patients with cancer pain deviate from prescribed analgesic regimens. 
Our aim was to elicit the trade-offs patients make based on their beliefs about analgesic 
use and rank utilities (importance scores) using maximum difference (MaxDiff) scaling. 
We also investigated if there were unique clusters of patients based on their analgesic 
beliefs. 
Methods: This was a secondary analysis of a three-month, prospective observational 
study. Patients (N=207) were self-identified African Americans and Whites, >18 years, 
diagnosed with multiple myeloma or solid tumor, and were prescribed at least one 
around-the-clock analgesic for cancer pain. MaxDiff analysis allowed us to identify 
patients utilities. Second, a cluster analysis assisted in ranking how analgesic beliefs 
differed by groups. Third, clusters were described by comparing key sociodemographic 
and clinical variables.  
Results: Participants’ beliefs were a significant factor in choices related to analgesic use 
(chi-square = 498.145, p < .0001). The belief, ‘Pain meds keep you from knowing what is 
going on in your body’, had the highest patient endorsement. Two distinct clusters of 
patients based on analgesic beliefs were identified; ‘knowing body’ was ranked as top 
priority for both clusters. The belief that cancer patients become addicted to analgesics 
was moderately important for both clusters. Severity of side effects was the only key 
variable significantly different between clusters (p = .043).  
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Conclusions: Our findings support tailored pain management interventions that attend to 
individual beliefs about cancer pain and analgesic use. Future research should explore the 
relationship between analgesic utilities, actual analgesic taking behaviors, and how they 





















Patient Trade-Offs Related to Analgesic Use for Cancer Pain:  
A MaxDiff Analysis Study 
The health and policy implications of the current opioid addiction epidemic 
require an increased scientific focus on tailored and person-centered pain management 
interventions (National Academies of Sciences, 2017; National Academy of Medicine, 
2017). This is particularly relevant for patients with cancer, given a well-documented 
high prevalence of cancer pain. In a systematic review and meta-analysis of 112 studies 
on pain and pain severity, roughly two-thirds of advanced cancer patients reported ‘some 
pain’ and about 38% of all cancer patients described their pain as ‘moderate’ to ‘severe’ 
(van den Beuken-van Everdingen, Hochstenbach, Joosten, Tjan-Heijnen, & Janssen, 
2016). Pain has also been endorsed as one of the top three most burdensome symptoms 
negatively affecting health-related quality of life for patients (N=4,903) in the year 
following cancer diagnosis (Shi et al., 2011). In this time of opioid crisis, there are noted 
inconsistencies in pain management guidelines and competing priorities among scientific 
and policy institutions that potentially complicate pain-related patient outcomes 
(Meghani & Vapiwala, 2018). 
Despite much debate, analgesics – and opioids in particular - remain central to the 
management of moderate to severe cancer-related pain (National Comprehensive Cancer 
Network [NCCN], 2019; Paice et al., 2016; World Health Organization [WHO], 2018). 
Although pain management guidelines assist in clarifying the salience of analgesic use 
for clinicians, there continues to be a critical paucity of empirical data exploring the 
trade-offs employed by patients in their decisions to use analgesics for cancer pain. This 
knowledge deficit is critical to address, given the high rates of analgesic nonadherence 
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for cancer pain identified in previous studies (Meghani et al., 2014; Meghani & Knafl, 
2017; Meghani, Thompson, Chittams, Bruner, & Riegel, 2015; Oldenmenger, Sillevis 
Smitt, de Raaf, & van der Rijt, 2017; Rhee, Kim, & Kim, 2012). Inconsistent analgesic 
use for cancer pain has been noted as both a strong predictor of increased healthcare 
resource utilization (Meghani & Knafl, 2016) and a predictor of poor pain-related and 
associated quality of life outcomes (Manzano, Ziegler, & Bennett, 2014).  
In response to both the documented need for individualized pain treatment and 
notable literature gap regarding patient heuristics, this study uses an innovative analytical 
technique -  maximum difference (MaxDiff) scaling - to elicit the analgesic trade-offs 
patients with cancer employ based on their pain management beliefs. Although MaxDiff 
has traditionally been used to identify consumer preferences among brands or items, it 
has become an attractive technique to elicit importance scores, also known as utilities, in 
relation to phenomena within the social sciences domains (Feudtner et al., 2015; J.J. 
Louviere, Flynn, & Marley, 2015; Mooney-Doyle, Deatrick, Ulrich, Meghani, & 
Feudtner, 2018; October, Fisher, Feudtner, & Hinds, 2014). In other words, individuals’ 
trade-offs reflect desirability of a given choice, thereby reflecting the amount of value the 
individual derives from that choice. 
Prior investigations have used trade-off analysis techniques, such as choice-based-
conjoint analysis, to identify analgesic treatment utilities (e.g. trade-offs between type of 
analgesic, side-effects type, side-effect severity, % pain relief from using analgesics, and 
out-of-pocket cost of analgesics) among cancer outpatients and minority subgroups 
(Meghani, Chittams, Hanlon, & Curry, 2013; Meghani & Knafl, 2017). However, to our 
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knowledge, this is the first study to understand the role of analgesic beliefs in these trade-
offs. Using MaxDiff analysis, the specific aims of this study are to: (1) identify patient 
trade-offs based on analgesic treatment beliefs; (2) rank and describe the utilities 
prioritized by patients using a MaxDiff-derived k means cluster analysis; and (3) describe 
the clusters in terms of key sociodemographic and clinical variables. Thus, these authors 
seek to determine patients’ trade-off on analgesic treatment beliefs, rank each belief 
according to the perceived value assigned by the participants, identify if there are any 
unique clusters based on participants’ ranking of each belief, and describe the identified 
clusters based on participants’ sociodemographic and clinical characteristics.  
Methods 
 
Sample and Setting 
This is a secondary analysis of an existing dataset (NIH/NINR RC1-NR011591: 
PI Meghani, S.H.; (Meghani et al., 2015). The parent study used a three-month 
prospective observational design with repeated measures (baseline, T1 and 3-month 
follow-up, T2). The primary aim of the parent study was to identify cancer pain 
management and analgesic adherence disparities between African-American and White 
patients. Convenience sampling was used to recruit from two outpatient medical 
oncology services at the Hospital of the University of Pennsylvania, Philadelphia, PA 
between December 2009 and August 2011. Approval for the parent study was obtained 
from the University of Pennsylvania Institutional Review Board (IRB) and all patients 
provided written informed consent.  
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Inclusion criteria consisted of patients 18 years or older who self-identified as 
White or African-American, were diagnosed with solid tumor  or multiple myeloma, 
reported cancer pain, and had at least one prescription of oral around-the-clock analgesic. 
Patients receiving pain control through a transdermal system were excluded.  
A sample of 241 subjects agreed to participate in the parent study. There was an 
estimated 14% attrition rate between T1 and T2 and 207 subjects completed the study 
(participant recruitment flow diagram published previously in Meghani et al. (2015). Of 
note, there was no disproportionate attrition by race or health status in the parent study. 
For the purpose of this analysis, data are used for the 207 subjects who completed the 
parent study at T2.  
The current study was deemed exempt by the University of Pennsylvania IRB as 
all data were previously de-identified of protected health information and, therefore, does 
not meet the definition of human subjects research.  
Measures 
Analgesic beliefs and barriers: The Barriers Questionnaire-II (BQ-II) (Ward et 
al., 1993), a 27-item self-report instrument, was used to evaluate how patients’ beliefs 
function as barriers to optimal cancer pain management (internal consistency 
reliability=0.89). The BQ-II evaluates pain management concerns across eight domains, 
including fears of analgesic addiction, tolerance, or side effects; cancer pain fatalism; a 
desire to be a ‘good patient’; fears that pain will distract the health provider from 
focusing on cancer treatment or that analgesics will harm the immune system; and 
concern that analgesics mask underlying illness processes.  
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Analgesic side-effects: The Medication Side-Effects Checklist (MSEC) was used 
to assess the presence and severity of analgesic side-effects (internal consistency 
reliability=0.80) (Ward, Carlson-Dakes, Hughes, Kwekkeboom, & Donovan, 1998). The 
MSEC identifies eight common side-effects related to analgesic use: constipation, 
drowsiness, nausea, vomiting, confusion, dry mouth, stomach irritation, and itching. 
Presence of side effects is elicited with a numerical scale, 0-8; severity of side-effects is 
measured with a numerical scale, 8-80 (from ‘not severe’ to ‘extreme severity’).  
Pain severity and pain-related function: Pain severity was assessed using the 
Brief Pain Inventory (BPI). The two subscales of the BPI include a 4-item pain intensity 
measure and a 7-item pain-related functional interference score (based on general 
activity, mood, walking ability, normal work, relationships, sleep, and life enjoyment) 
(Cleeland & Ryan, 1994). Items are scored on a 0-10 scale (no pain – pain as bad as you 
can imagine; no interference – worst possible interference). The BPI maintains a 
Cronbach’s alpha ranging from 0.77 to 0.91 in its use among cancer patients (Anderson et 
al., 2002; Cleeland et al., 1994). 
Pain Management Index: Based on the WHO’s cancer pain management 
guidelines (1986, 1996, 2018), Pain Management Index (PMI) is frequently used to 
measure the adequacy of analgesic treatment in cancer patients. PMI offers a comparative 
score of the most potent analgesic used in relation to the patient’s reported pain. PMI is 
calculated by taking the most potent analgesia used according to the WHO’s 3-step 
cancer pain analgesic ladder and subtracting the patient’s worst pain BPI score. A 
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negative PMI implies inadequate analgesic prescription strength given reported pain 
level. 
Social support questionnaire: Subjects’ level of social support and satisfaction 
with perceived social support was elicited using a 6-item instrument (an abbreviated 
version of the 27-item Social Support Questionnaire) (Sarason, Levine, Basham, & 
Sarason, 1983). There are two parts to the question: first, subjects list the individuals in 
their life who provide social support and, second, they provide their satisfaction level 
with the support.  
Prescribed analgesics: Prescribed analgesics were classified per the WHO (1986, 
1996, 2018) cancer pain analgesic ladder. Categories include step 1 (nonopioids, e.g. 
nonsteroidal anti-inflammatories), step 2 (weak opioids, e.g., tramadol, codeine), and step 
3 (strong opioids, e.g., methadone, oxycodone, morphine).  
 Sociodemographic and clinical variables: Self-reported sociodemographic data 
collected were age, gender, self-identified race, marital status, education, health 
insurance, household income, and job status. Clinical variables including stage of cancer, 
time since cancer diagnosis, past history of alcohol or substance abuse, history of 
depression, and comorbidities were gathered from the patient’s medical record and used 
to calculate a Charlson Comorbidity Score (Charlson, Pompei, Ales, & MacKenzie, 
1987). Patients rated their general health on a five-point likert scale (from poor to 
excellent) and then indicated the number of days in the prior 30-day period in which they 
would rate their physical and mental health as “not good”. Pain and treatment related 
variables included: the duration of cancer pain and the type and numbers of prescribed 
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analgesics and coanalgesics used. Coanalgesics refer to medications used in conjunction 
with analgesics to optimize pain control, such as antidepressants, benzodiazepines, or 
neuropathic agents. 
Statistical Analysis 
 MaxDiff analysis was completed using JMP Pro 14 software. Descriptive 
statistics were computed on Stata/IC 15. First, descriptive statistics were generated for 
sociodemographic and clinical variables (e.g., means and standard deviations for 
continuous variables, frequencies and percentages for categorical variables).   
Trade-Offs Based on Analgesic Beliefs 
Trade-offs for the sample (N=207) were derived using a MaxDiff analysis. 
MaxDiff is a trade-off methodology derived from Random Utility Theory (Thurstone, 
1927). MaxDiff maintains noted measurement advantages over traditional survey 
techniques, other ranking methods and some discrete choice analyses methods, which 
may confuse participants with too many options in a given choice set and/or muddle 
findings by lacking clear measurement differences between choices (Louviere, Flynn, & 
Carson, 2010; Marley & Flynn, 2015). Ultimately, MaxDiff allows for (1) increased 
discrimination through forced tradeoffs among items and between subjects’ responses on 
the given items; (2) demonstrates optimal ease of use for respondents from diverse 
education and cultural backgrounds; and (3) avoids scale use bias by requiring 
respondents to make choices rather than merely rating the strength of their preferences 
(Sawtooth Software, 2019).  
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MaxDiff requires subjects to identify both the ‘best’ and ‘least desirable’ option 
available within a given set of choices (Finn & Louviere, 1992; Marley & Louviere, 
2005). Thus, it is also referred to as ‘best-worst scaling’ and identifies the ‘maximum 
difference’ in preference between the ‘best’ and ‘worst’ choices available (Marley & 
Flynn, 2015). Subjects in this current study selected the belief statement, also known as 
an attribute, that was “most” and “least” important in thinking about his or her pain 
medications. Responses allowed us to calculate the maximum difference between patient 
responses across eight distinct choice sets. The barriers elicited were based on the 
validated Barriers Questionnaire-II (Ward et al., 1993). Table 1 lists the BQ-II domains 
(Ward et al., 1993). Abbreviated statements used to represent each of the questionnaire 
attributes in the following sections are also provided in Table 1. 
MaxDiff analysis results provided measures of marginal probability, which 
estimate the probability that a patient conveys a preference for the corresponding attribute 
over other listed attributes (SAS Institute, 2019). The marginal probabilities of all 
attributes sum to 1.00. MaxDiff analysis also captures measures of marginal utility, 
which indicate the perceived value of the corresponding attribute; hence, a larger utility 
suggests greater corresponding value to the patient (SAS Institute, 2019). The marginal 
utilities provide both positive and negative values and sum to 0. A chi-square likelihood 
ratio test was calculated as a part of this initial MaxDiff analysis to elicit whether 
patients’ analgesic beliefs were independent of their choices related to pain medications 




Unique Clusters Based on Analgesic Beliefs  
MaxDiff-derived utilities were subjected to a k-means cluster analysis. K means is 
a prototype-based clustering technique that applies one-level of partitioning using an 
unsupervised learning algorithm (Kaufman & Rousseeuw, 1990). K means produces non-
overlapping clusters, such that each data object is assigned to one cluster. This technique 
is preferred for this study since hierarchical or fuzzy clustering techniques would use 
nested or overlapping cluster membership that would complicate the process of 
identifying clear utility trade-offs (Tan, Steinbach, Karpatne, & Kumar, 2019).   
A goal with the k means clustering analysis algorithm is to find groups in the data 
with a pre-specified number of k centroids (Hastie, Tibshirani, & Friedman, 2009). Data 
is then assigned to its closest centroid using a Euclidean distance minimization equation. 
Next, centroids are recomputed in an iterative process until they show no further signs of 
change (Tan et al., 2019). The goal of clustering was to identify similarities among 
groups of individuals in how they prioritize their beliefs related to analgesic treatment. 
We selected a 2-cluster model a priori for analysis. Two clusters provided a cubic 
clustering criterion (CCC) of -1.95. A lower CCC represents a minimal within-cluster 
sum of squares (Tan et al., 2019). An ad hoc quality check confirmed smaller CCCs of -
2.31 and -2.18 for 3- and 4-cluster models respectively. A 5-cluster model provided the 
largest CCC at -0.24, however, for both parsimony and clarity, as well as the sample size, 
2 clusters were used.  
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Finally, MaxDiff utility rankings were calculated for each cluster using the 
MaxDiff analysis process, as described above (Sawtooth Software, 2013). These rankings 
sum to 100.  
Cluster Description by Sociodemographic and Clinical Variables 
Once clusters were identified and ranking completed, key sociodemographic and 
clinical variables were then recalculated for each cluster and statistical tests were used to 
identify significant differences between them used Stata/IC 15 (e.g., t-tests for continuous 
variables and chi-square for categorical variables). 
Results 
 
 On average, the subjects were 53.8 years (SD=11.1). The majority self-identified 
as White (58.5%), female (56.5%), and were college/trade-school educated (48.8%) or 
higher (15.9%) (Table 2). The vast majority of patients were diagnosed with a solid 
tumor and less than one-fifth had multiple myeloma. Just under one-third of patients had 
Stage IV cancer and more than half rated their general health as “fair” or “poor” in the 30 
days preceding data collection. Most patients were prescribed a strong (WHO step 3) 
opioid, classified as WHO step 3. In the week prior to the survey, on average patients 
reported a “worst pain” score of 6.9 on a 0-10 scale and reported about four different 
analgesic side effects.  
Trade-Offs Based on Analgesic Beliefs 
 MaxDiff analysis results for the sample (N=207) include marginal utilities and 
marginal probabilities for each of the questionnaire attributes (Figure 1). MaxDiff 
likelihood ratio testing suggests that patient beliefs (as represented by the survey 
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attributes) are a significant factor in their choices when thinking about pain medicines 
(chi-square = 498.145, p < .0001).  
‘Knowing body’ and ‘Immune system’ yielded the highest marginal probabilities. 
In essence, patients are 23.9% more likely to make trade-offs about analgesic medications 
based on ‘Knowing body’ than other competing beliefs. Similarly, ‘Knowing body’ had a 
marginal utility of 95.7%, meaning this belief was about twice as important to patients 
than ‘Immune system’ or ‘Need it later’, and more than four times as important in making 
trade-offs than ‘Addicted to meds’. Not only do patients with cancer identify ‘Knowing 
body’ as the most important belief but they are also more likely to make choices based on 
it when compared to other beliefs. 
 Four attributes on the questionnaire yielded negative marginal utilities scores, 
indicating no or limited perceived value of these beliefs in relation to pain medicines. 
These utilities included, ‘Doctors won’t focus on cancer’, ‘Be strong’; and ‘Say 
embarrassing things’. The utility of ‘Complainer’ was minimal at best and could not be 
measured using the data platform. Ultimately, patients are markedly less likely to trade-
off based on these four utilities than the beliefs reflected by the other survey attributes. 
Utility Ranking: MaxDiff-Derived Cluster Analysis 
 Using methods described previously, a 2-cluster model was selected. The parallel 
coordinate plot (Figure 2) displays the structure of the cluster observation means and 
illustrates more explicitly how cluster outcomes differ (discussed in more detail by 
cluster). Both clusters ranked ‘Knowing body’ as the most salient utility (Table 3); 
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supporting the trade-off findings previously discussed that this belief tends to be the most 
important for patients with cancer. 
 For cluster 1, ‘Side effects’ was ranked as 2nd most important. The least relevant 
utilities, ranked 9th and 10th respectively, were ‘Say embarrassing things’ and ‘Won’t 
focus on cancer’. This further strengthens the argument that these utilities have little or 
no perceived value and are, ultimately, of nominal importance in decisions related to pain 
medication.  There were some differences noted in cluster 2 rankings. The ‘Need it later’ 
utility was ranked 2nd among cluster 2 members. Bottom ranked utilities reflected beliefs 
related to ‘Complainer’ (9th) and ‘Say embarrassing things’ (10th), 
 ‘Addicted to meds’ was ranked fourth by both clusters, connoting a moderate 
level of importance for all patients in the sample. The prioritizing of ‘Addicted to meds’ 
in the top 50% of utilities by both clusters demonstrates a moderately high belief in 
addiction across the sample. While not the most or even the second most important 
utility, addiction to analgesics is a consistently relevant factor surrounding pain treatment 
beliefs.  
Overall, the clusters shared over 50% of the top five ranked utilities in common, 
as well as over half of their bottom five (Table 3). These results show that the 
prioritization of patient beliefs still varies significantly between clusters, demonstrating 
broader substantive differences among how cancer patients’ beliefs inform their thoughts 
about analgesic use. This variation reflects the differences in  individual beliefs and the 




Cluster Description in Terms of Sociodemographic and Clinical Variables 
Table 4 shows sociodemographic and clinical variables by cluster. Less than half 
of cluster 1 (n=53) self-identified as African-American (43.4%) and the majority were 
female (60.4%). This group rated their “worst pain” as slightly more severe than cluster 
2. Additionally, cluster 1 patients endorsed a significantly higher severity related to 
analgesic side effects than cluster 2 (p = 0.043). On average, cluster 1 patients were 
prescribed roughly two analgesic medications to alleviate their cancer pain, the majority 
of which were a strong opioid (WHO step 3). They also reported experiencing about four 
different analgesic side effects. The majority of cluster 2 (n=154) self-identified as White 
(59.1%) and female (55.2%) (Table 4). The number of analgesics (including strong 
opioids) prescribed and the number of side effects experienced were very similar to 
cluster 1. Patients in cluster 1 and cluster 2 did not vary significantly in age, gender, race, 
or other sociodemographic variables (Table 4). Other clinical variables included in the 
analysis showed no statistically significant differences.  
Discussion 
 
In our study, we first sought to identify patient trade-offs based on analgesic 
treatment beliefs using a MaxDiff analysis. We subsequently ranked the utilities 
prioritized by patients using a k means cluster analysis and then described the clusters in 
terms of key sociodemographic and clinical variables. To our knowledge, this is the first 
study to use the MaxDiff methodology in this context. Previous studies have noted that 
patients with cancer pain stop taking their analgesics for a number of reasons. Some of 
these include the severity of side effects (Manzano et al., 2014; Meghani & Bruner, 2013; 
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Meghani et al., 2015); concern regarding the physiological consequences of opioid use, 
such as dependence or addiction (Jacobsen et al., 2014; Simone, Vapiwala, Hampshire, & 
Metz, 2012); a firm conviction that clinicians should focus on treating the cancer rather 
than pain (Rhee et al., 2012); and the hesitancy of patients’ family and caregivers to use 
analgesics (Lee et al., 2015; Schumacher et al., 2014). Our analysis suggests that patient 
trade-offs based on certain beliefs about cancer pain management yield a significant 
influence in their choices about analgesic use. This finding is consistent with previously 
demonstrated empirical links between analgesic beliefs and analgesic nonadherence 
behaviors (Liang et al., 2013; Meghani & Bruner, 2013; Torresan et al., 2015; Valeberg, 
Miaskowski, Paul, & Rustoen, 2016). Despite these study findings, we still know little 
about how patients make the decision to use analgesics based on their beliefs.  
A striking result was that the belief, ‘Many people with cancer get addicted to 
meds’, was not a top priority for participants. In fact, this utility was ranked 4th and found 
to be of only moderate importance among both clusters. One may have anticipated a 
higher importance score related to addiction beliefs given these data were collected at the 
height of the opioid addiction epidemic. Despite some studies that suggest a worry about 
dependence or addiction to opioids as significant in the patient decision-making process 
(Jacobsen et al., 2014; Liang et al., 2013; Simone et al., 2012), researchers have argued 
that addiction concerns do not explain objective analgesic adherence in the cancer pain 
population (Meghani et al., 2015). In addition, this finding is consistent with other 
evidence showing that although a significant number of patients express some concern 
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about addiction to opioids, this belief is also not correlated with subjective measures of 
adherence (Rhee et al., 2012).    
Participants across the sample consistently prioritized the ‘Pain meds keep you 
from knowing what is going on in your body’ utility with the highest level of importance. 
This result validates the emphasis patients place on knowing their own bodies (‘Knowing 
body’) in thinking about their pain medications. Furthermore, this belief may yield more 
significant trade-off power over other beliefs and may directly correlate with a patients’ 
likelihood to use analgesics to mitigate their cancer pain burden. Future research should 
examine these issues.  This finding of knowing one’s body emphasizes how important it 
is to cancer patients to have a firm understanding of their underlying physiological 
processes.  
The high relevance of knowing one’s body validates the results of several 
previous empirical studies. Investigators found that cancer patients with higher rates of 
intentional analgesic nonadherence were more likely to agree with the ‘Knowing body’ 
statement (Meghani & Bruner, 2013). In a recent survey of patients with different 
cancers, the presence of pain was significantly linked to the status of disease (Rau et al., 
2017), which may explain how patients use pain to better understand their bodies and 
why they stop taking analgesics accordingly. Other findings suggest that some patients 
deny pain as a symptom of disease, which may increase barriers to analgesic utilization 
(Torresan et al., 2015). Another study by Liang and colleagues (2013) showed that about 
one-third of patients believe opioids should only be used late in the disease process, 
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consistent evidence that analgesics may become more acceptable once patients feel they 
have a clearer understanding of what is going on in their bodies.  
 Consistent with previous research that associates increased side effects and side 
effects severity with decreased analgesic adherence (Manzano et al., 2014; Meghani & 
Bruner, 2013; Meghani et al., 2014), our cluster analysis findings highlights the 
importance of addressing patients’ side effects when using analgesics for cancer pain. In 
addition, the severity of side effects also differed significantly between cluster 1 and 
cluster 2, further suggesting that the utility of ‘Side effects’ may be a salient concern for 
some and not others. For example, an earlier study involving this sample concluded that 
more than a quarter of patients were found to make trade-offs based on multiple 
concerns, including both type and the severity of side effects (Meghani & Knafl, 2017).  
‘If you use pain medicine now, it won’t work when you need it later’ was ranked 
among the top two utilities for cluster 2. In other words, a worry about tolerance to 
analgesics may be a likely concern for patients with cancer pain. This utility is informed 
by the belief that if patients with cancer pain take analgesics whenever they need it, then 
those same medications will not be effective when the pain increases in severity and the 
need for relief is more substantial. This correlates with a study that showed  a majority of 
patients agree that using an opioid in earlier disease stages will prevent its optimal effect 
later (Liang et al., 2013). Some trade-offs, such as ‘Won’t focus on cancer’, ‘Be strong’; 
‘Say embarrassing things’; and ‘Complainer’, were found to have low utility. These 
findings are in alignment with a previous study showing that these beliefs tend to have 
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less importance among patients with cancer pain than ‘Knowing body’ or ‘Immune 
system’ (Valeberg et al., 2016). 
Clinical Implications 
 
A number of relevant clinical implications are suggested. First, clinicians who 
prescribe and administer analgesics to treat cancer pain should elicit patients’ analgesic 
beliefs in order to ensure safe use and minimize adverse outcomes. The analgesic 
treatment priorities and beliefs of patients may not always be aligned with the priorities 
of clinicians, such as the case with addiction concerns. Second, analgesic regimens 
should be determined in partnership with patients to ensure patients’ beliefs are optimally 
considered in creating prescription pain treatment plans. Prescribing in partnership 
requires the integration of patient-centered care with evidence-based pain guidelines, 
which are currently severely lacking, specially for opioid pain management for cancer 
pain (Meghani & Vapiwala, 2018). Third, optimizing nonopioids and weak opioids that 
cause fewer adverse effects per the WHO (1986, 1996) cancer pain ladder may address 
patients’ beliefs. However, it must be emphasized that many guidelines continue to 
suggest the use of strong opioids in the treatment of moderate to severe cancer pain 
(NCCN, 2019; Paice et al., 2016; WHO, 2018). Fourth, our findings support well-cited 
recommendations in academia and policy calling for tailored patient education related to 
opioid use, risks, and benefits (Christie et al., 2017; National Academies of Sciences, 
2017; National Academy of Medicine, 2017; Oldenmenger et al., 2018). As future 
research elucidates the link between individual beliefs and actual analgesic taking 
behaviors, interventions related to analgesic prescribing and education should aim to 
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become more patient-centric. It is imperative that the relationship between beliefs and 
analgesic adherence be further clarified for the sake of improved patient safety and health 




 There were several limitations to consider. First, the data was collected between 
2009 and 2011; this time period, however, overlapped with the second wave of the opioid 
crisis (Centers for Disease Control & Prevention, 2018), making the findings highly 
relevant to the current sociopolitical milieu. Second, the sample is limited to patients who 
self-identify as either African-American or White, excluding the utilities of patients from 
other diverse backgrounds. Additional studies might examine if differences exist among 
other ethnic, racial, and minority populations. Third, the parent study questionnaire 
provided patients with ten attribute statements assessed through eight different choice 
sets. There are a broad variety of attributes that were likely not included in our study. In 
the future, researchers may consider a more extensive attribute list, as well as the 
integration of qualitative methods to validate findings and cultivate a deeper 
understanding of this phenomenon. Finally, provider-, family-, and system-level factors 
and their influence on analgesic use were not accounted for in the MaxDiff analysis. 
Ongoing investigations might combine family and provider factors along with patient 







 There is much yet to be explored about how beliefs and resultant utilities factor 
into analgesic use and overall adherence in the management of cancer pain. In better 
understanding the trade-offs made by patients, prescribers have improved opportunity to 
tailor pain treatment strategies to individual needs. The current climate of the opioid 
crisis and its broad implications in practice, policy, and research require investigators and 
clinicians to cultivate a deeper understanding of how patients’ beliefs inform their 
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Table 1. Attributes for MaxDiff Analysis with Abbreviations Based on Barriers     
     Questionnaire-II (BQ-II) Domains. 
BQ-II Domains                    
(Ward et al., 1993) 
Attributes for MaxDiff Analysis Abbreviated Attribute 
Statement 
1. Fear of addiction.  Many people with cancer get 
addicted to pain meds.  
 
 Addicted to meds 
2. Fear of tolerance.  If you use pain medicine 
now, it won’t work when 
you need it later.  
 
 Need it later 
3. Fear of side effects.  It is easier to deal with the 
pain than the side effects that 
come from the pain meds.  
 
 Pain meds make you say or 
do embarrassing things.  
 




 Say embarrassing 
things 
4. Fatalism about cancer pain.   Cancer pain cannot be 
relieved with medications.  
 
 Cannot be relieved 
5. Desire to be a good patient.   If I talk about pain, people 
will think I’m a complainer.  
 
 It is important to be strong 





 Be strong 
6. Fear of distracting health 
provider from treating 
cancer. 
 If doctors have to 
concentrate on pain they 
won’t focus on treating the 
cancer.  
 
 Won’t focus on 
cancer 
7. Fear that analgesics impair 
the immune system. 
 
 Pain meds weaken the 
immune system.  
 Harm immune 
system 
8. Concern that analgesics 
may mask ability to 
monitor illness symptoms.  
 Pain meds keep you from 
knowing what is going on in 
your body.   




Table 2. Relevant Sociodemographic, Illness, and Pain-Related Characteristics (n=207). 
Variable 
 
Range n(%)1 Mean (SD) 































Job status Full-time outside home 
Part-time outside home 
Full-time at home 

























Health literacy 3-15  13.1 (2.6) 
Social support 0.17-9.00  3.7 (2.1) 
























Time since cancer 
diagnosis 
1-120 months  36.7 (35.5) 
Charlson comorbidity 
index 
0-13  4.3 (2.6) 











Physical health not good 
(within past 30 days) 
0-30  14.7 (10.7) 
Mental health not good 
(within past 30 days) 
0-30  9.5 (10.7) 
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Index analgesic  WHO Step 1 
WHO Step 2 





Average pain (last 
week) 
0-10 (no pain - pain as bad as 
you can imagine) 
 4.9 (2.1) 
Pain-related functional 
interference score 
7-70 (does not interfere - 
interferes completely) 
 35.2 (15.9) 















0-135  66.8 (20) 
Number of analgesic 
side-effects (MSEC) 
0-8  3.8 (2.4) 
Severity of analgesic 
side-effects (MSEC) 
8-80 (not severe – extremely 
severe) 
 25.2 (15.0) 
 
1No missing values unless otherwise noted. SD: Standard deviation.  






Table 3. MaxDiff Utilities Ranked by Cluster 





Cluster 2 (n=154)                         
Mean (SD) 
Knowing body 14.204   
(6.266) 
1 Knowing body 17.388  
(6.699) 
Side effects 13.899  
(5.573) 
2 Need it later 15.015  
(7.415) 
Be strong 12.353  
(7.603) 
3 Harm immune system 14.137 
(6.568) 
Addicted to meds 11.949 
(9.015) 
4 Addicted to meds 13.560 
(9.040) 
Need it later 11.380 
(6.415) 




6 Won’t focus on cancer 9.838 
(8.198) 
Harm immune system 8.254 
(5.751) 
7 Side effects 9.830 
(4.730) 
Cannot be relieved 6.579 
(5.466) 
8 Be strong 4.333 
(4.202) 
Say embarrassing things 6.344 
(5.687) 
9 Complainer 2.066 
(3.064) 
Won’t focus on cancer 4.993 
(5.286) 
10 Say embarrassing things 1.927 
(1.959) 
*The middle column provides a rank order numbered 1-10. The two left-hand columns 
provide the order of cluster 1 utilities based on rescaled MaxDiff probabilities. Similarly, 
the two right-hand columns provide the order of cluster 2 utilities. 
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Table 4. Key Clinical Variables by Cluster. 
Variable Cluster 1 (n=53) Cluster 2 (n=154) P-value[a]* 
Mean (SD) 
Age (years) 54.2 (12.5) 53.7 (10.7) 0.798 
Duration of disease (months)  30.5 (29.4) 38.9 (37.2) 0.138 
Charlson Comorbidity Score (0-
13) 
4.4 (2.3) 4.3 (2.8) 0.725 
Social Support Amount (0.17-
9.00) 
4.1 (2.3) 3.6 (2.0) 0.102 
General health not good (number 
of days within last 30 d) 
3.5 (1.0) 3.5 (1.1) 0.862 
Physical health not good (number 
of days within last 30 d) 
15.7 (11.3) 14.4 (10.5) 0.439 
Mental health not good (number of 
days within last 30 days) 
8.3 (10.1) 9.9 (10.9) 0.333 
Pain Management Index (-2 - +3) 0.5 (0.8) 0.6 (1.0) 0.687 
Number of analgesics (excluding 
coanalgesics) WHO Step 1 
0.3 (0.5) 0.2 (0.4) 0.410 
Number of analgesics (excluding 
coanalgesics) WHO Step 2 
0.2 (0.4) 0.3 (0.6) 0.087 
Number of analgesics (excluding 
coanalgesics) WHO Step 3 
1.7 (1.0) 1.5 (0.8) 0.099 
Total number of analgesics 
prescribed (excluding 
coanalgesics) 
2.2 (1.0) 2.0 (0.8) 0.309 
Worst pain (0-10) 7.1 (2.0) 6.8 (2.5) 0.530 
Number of analgesic side effects 
(MSEC, 0-8) 
 
4.1 (2.4) 3.7 (2.5) 0.266 
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Severity of side effects (MSEC, 0-
80) 
28.8 (15.6) 24 (14.6) 0.043 
Health literacy (3-15) 13.3 (2.7) 13.0 (2.6) 0.413 
Barriers Questionnaire-II (BQ-II, 
0-135) 
63.7 (19.4) 67.8 (20.2) 0.200 
Frequency (%) 
Race 
  African-American 









  Male 









  Married 
  Separated 
  Divorced 
  Widowed 















  Elementary 
  High school 
  College/trade school 













  < 30,000 










  50,000-70,000 
  70,000-90,000 








  Private 
  Medicare 
  Medicaid 
  Multiple  















  Full-time outside home 
  Part-time outside home 
  Full-time at home 
  Part-time at home 
  Retired  
  Unemployed 



















  I 
  II 
  III 
  IV 





























  Lung 
  Breast 
  Gastrointestinal 
  Genitourinary/reproductive 
  Multiple myeloma 











History of substance abuse 
  Yes 
























Figure 1. MaxDiff Marginal Utility and Marginal Probability.  
 
 
*Attributes are listed in descending order by marginal utility (left) and marginal 














Figure 2. Parallel Coordinate Plot: MaxDiff Cluster Means. 
 
 
*Observation means of rescaled marginal probabilities by cluster. This plot presents 










The Association Between Analgesic Treatment Belief Clusters and 
























Objectives: To determine if clusters based on cancer patients’ analgesic treatment beliefs 
predicted objective analgesic adherence as measured by an electronic medication 
monitoring system while accounting for relevant confounders. 
Sample and Setting: The sample (N=207) consisted of outpatient oncology patients, > 
18 years, self-identified as White or African-American, diagnosed with solid tumor or 
multiple myeloma, and prescribed at least one around-the-clock analgesic prescription for 
reported cancer pain. 
Methods and Variables: This is a secondary analysis of an existing dataset. We applied 
general linear modeling with a backward elimination approach to determine if previously 
identified analgesic treatment belief clusters were associated with adherence behaviors. 
Results: Significant explanatory factors were experiential in nature and included 
sociodemographic, clinical, and pain-related variables (p < 0.05), explaining 21% of the 
variance in analgesic adherence. Analgesic belief clusters were not predictive of 
adherence.  
Implications for Nursing: Future research should examine sociodemographic and other 
clinical factors, as well as the influence of analgesic treatment beliefs, to better 
understand analgesic adherence behaviors.   
Knowledge Translation: Oncology nurses should address the experiential factors 
affecting analgesic adherence, become aware of evolving pain management strategies 
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amid the opioid epidemic, and understand how the notion of ‘adherence’ may change 























The Association Between Analgesic Treatment Belief Clusters and  
Electronically-Monitored Analgesic Adherence for Cancer Pain  
The majority of patients with cancer report pain and as many as 38% report their 
pain as moderate to severe (Shi et al., 2011; van den Beuken-van Everdingen, 
Hochstenbach, Joosten, Tjan-Heijnen, & Janssen, 2016). Although there is a lack of data 
on outcomes related to long-term opioid use for cancer pain (Meghani & Vapiwala, 
2018), a number of cancer pain guidelines continue to identify opioids as a core 
component of moderate to severe cancer pain management (National Comprehensive 
Cancer Network [NCCN], 2019; Paice et al., 2016; World Health Organization [WHO], 
2018). While some pain management guidelines promote the use of complementary and 
alternative strategies (Dowell, Haegerich, & Chou, 2016; NCCN, 2019), their 
affordability may be unmanageable for some and several systematic reviews have noted 
insufficient evidence to support their clinical efficacy in alleviating cancer pain (Hetkamp 
et al., 2019; Kim, Loring, & Kwekkeboom, 2018; Kim, Kang, & Lee, 2018; Shin et al., 
2016; Wayne et al., 2018). Thus, analgesic use - and opioid use in particular - remains a 
primary modality for achieving moderate to severe pain control in the cancer population. 
Although there are a number of national initiatives underway that focus on advancing 
pain science from the provider perspective (National Academies of Sciences, 2017, 2020; 
National Academy of Medicine, 2017), we still know little about the predictors of 
patients’ actual analgesic taking behaviors.  
Given the opioid epidemic and its healthcare implications, the phenomenon of 
analgesic adherence requires better understanding. Patients who experience less pain 
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relief with analgesic use or higher side effect severity are typically less adherent to 
prescribed analgesic regimens, whereas those prescribed a strong opioid (classified as 
WHO step 3) or a long-acting opioid show higher levels of adherence (Meghani, 
Thompson, Chittams, Bruner, & Riegel, 2015). Patient beliefs have been shown to 
predict adherence behaviors. For example, patients who believed their doctor should 
focus on curing illness over treating pain demonstrated increased adherence behaviors. 
Inconsistent analgesic adherence for cancer pain has been correlated with increased 
hospitalization rates (Meghani & Knafl, 2016), as well as poor pain and quality of life 
outcomes (Manzano, Ziegler, & Bennett, 2014). In addition, the patients with higher 
hospitalization rates shared a belief that pain medicine can harm the immune system 
(Meghani & Knafl, 2016).  
Understanding how patient beliefs inform decisions to use prescribed analgesia is 
an important aspect of improving pain management strategies and subsequent outcomes 
(Miaskowski et al., 2001). Researchers have identified distinct patient clusters based on 
how patients make trade-offs (e.g. type of analgesic, type and severity of side-effects, 
amount of expected pain relief, and out of pocket costs) in considering analgesic 
treatment for cancer pain (Meghani & Knafl, 2017). Using choice-based conjoint 
analysis, these researchers found that a majority of patients may be motivated 
predominantly by a single salient concern in their decision to use analgesia for cancer 
pain (Meghani & Knafl, 2017).  
We previously found two unique clusters of patients based on how they 
prioritized their beliefs about analgesic treatment for cancer pain (Rosa, Chittams, Riegel, 
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Ulrich, & Meghani, 2019). These analgesic treatment belief clusters were identified using 
a decision-making trade-off methodology known as maximum difference scaling to elicit 
what beliefs are most important to patients when thinking about analgesic use for cancer 
pain management. Patients in our study were most likely to trade-off based on the belief 
that taking pain medicine would keep patients from knowing what is going on in their 
body (Rosa et al., 2019). A belief that patients who take analgesic for cancer pain become 
addicted was only moderately important across the sample. (Rosa et al., 2019). Our 
specific aim for this paper is to assess whether these unique analgesic belief clusters 
predict objective analgesic use as measured by an electronic medication monitoring 
system while accounting for relevant confounders. 
Methods 
 
Design and Study Population 
 This study is a secondary analysis of existing data (NIH/NINR RC1-NR011591: 
PI Meghani, S.H.).  The goal of the parent study was to explain racial and ethnic 
disparities in cancer pain outcomes, specifically to elicit trade-offs that patients with 
cancer pain employ in making cancer pain treatment decisions (using Choice-based 
Conjoint analysis) and their actual adherence to scheduled analgesic treatment using 
electronic monitoring with the Medication Event Monitoring System (MEMS®) 
(Meghani et al., 2013; Meghani et al., 2015). The parent study used a prospective 
observational design employing repeated measures at baseline (T1) and 3-month follow-
up (T2). Patients were recruited from two outpatient medical oncology clinics of the 
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University of Pennsylvania Health System in Philadelphia between December 2009 and 
August 2011. The Institutional Review Board (IRB) of the University of Pennsylvania 
approved the parent study and all participants provided written informed consent.  
The current study was deemed exempt by the University of Pennsylvania 
Institutional Review Board (IRB) as all protected health information was removed from 
the dataset prior to study commencement and, therefore, it did not meet the definition of 
human subjects research. Consistent with the parent study, the criteria specified inclusion 
of patients 18 years of age or older who self-identified as African-American or White, 
reported a diagnosis of multiple myeloma or solid tumors, endorsed cancer pain, and had 
been prescribed at least one around-the-clock (ATC) oral analgesic. Patients using 
transdermal opioid delivery systems, such as fentanyl, were not included in the parent 
study sample due to MEMS® vial limitations. This current sample includes 207 self-
identified African-American and White patients (participant recruitment flow chart from 
the parent study was previously published (Meghani et al., 2015); a 14% attrition rate was 
noted between T1 (N=241) and T2 (N=207) with no statistically significant attrition 
identified by participants’ health status or race) (Meghani et al., 2015).  
Study Measures 
Electronically-Monitored Analgesic Adherence using MEMS® 
The MEMS® (MVW Switzerland Ltd., Sion, Switzerland) was employed to 
measure objective analgesic adherence. MEMS® is a medication bottle cap that uses a 
microprocessor to record in real time the event and time of a bottle opening. “Dose 
126 
 
adherence” was the primary measure of adherence to ATC analgesics, defined as the 
percentage of the total number of prescribed doses that were taken by a patient. For 
instance, if a patient took 80 of 100 prescribed doses during the period of the study, “dose 
adherence” would be 80%. The procedures for calculating dose adherence were 
previously described in the parent study (Meghani et al., 2015). Investigators in the 
parent study performed sensitivity analysis to account for the observer effect (e.g., 
modified analgesic taking behavior due to awareness of being observed) and compared 
MEMS® dose adherence from the total number of study days to MEMS® dose 
adherence if the first 30 days of observation were removed (Meghani et al., 2015). 
Significant Spearman correlations for all patients in the sample (P < .001) suggested 
strong internal consistency between total dose adherence scores for the study duration 
and the total dose adherence scores minus the first 30 days of observations. Based on 
these findings, (Meghani et al., 2015) the MEMS® dose adherence scores measuring all 
monitored days in the study was selected for use in the final analysis.  
Index Analgesic 
 Around-the-clock analgesics (index medications) were self-reported by patients 
during the T1 baseline interview and confirmed through a review of electronic medical 
records. Index analgesics were classified per the WHO’s (1986, 1996) analgesic ladder. 
Categories include step 1 (nonopioids, e.g., nonsteroidal anti-inflammatories such as 
ibuprofen or acetaminophen), step 2 (weak opioids, e.g., codeine, tramadol), and step 3 
(strong opioids, e.g., methadone, oxycodone).  
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Analgesic Beliefs for Cancer Pain 
 Maximum difference (MaxDiff) scaling was used to derive patient clusters based 
on beliefs about analgesic treatment for cancer pain. Cluster membership was originally 
identified using MaxDiff statistical techniques on JMP Pro 14 software as previously 
described (Rosa et al., 2019). MaxDiff is a trade-off methodology rooted in Random 
Utility Theory (Thurstone, 1927). It permits researchers to elicit increased choice 
discrimination through forced trade-offs between items and prevents scale use bias by 
requiring subjects to make clear choices rather than merely rating preference strengths as 
used in other ranking or discrete choice methods (Louviere, Flynn, & Carson, 2010; 
Louviere, Flynn, & Marley, 2015; Marley & Flynn, 2015; Sawtooth Software, 2019). 
MaxDiff data were then subjected to a k means cluster analysis. Two unique clusters 
were identified: cluster 1 (n=53) and cluster 2 (n=154), which correlated with distinct 
analgesic treatment preferences. Since both clusters shared the same top ranked analgesic 
belief, cluster 1 was named the “Side effects” cluster and cluster 2 the “Need it later” 
cluster based on the second highest ranked preference of each group. Additional 
information on the rationale for the two-cluster model is provided in a previous 
publication (Rosa et al., 2019). 
Self-Reported Barriers to Analgesic Use 
The Barriers Questionnaire-II (BQ-II) (Ward et al., 1993) is a 27-item instrument 
used at baseline (T1) to assess patient beliefs and concerns about cancer pain 
management. Eight domains related to pain management concerns comprise the BQ-II: 1) 
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fear of addiction; 2) fear of tolerance; 3) fear of side-effects; 4) fatalism about cancer 
pain; 5) desire to be a good patient; 6) fear of distracting healthcare providers from 
treating cancer; 7) fear of immune system impairment through analgesic use; and 8) 
concern about analgesic use masking a patient’s ability to monitory the physiological 
symptoms of his or her illness. The BQ-II demonstrates strong internal consistency at .89 
(Ward et al., 1993) and measured .86 in this study.  
Analgesic Side Effects 
The Medication Side-Effects Checklist (MSEC) (Ward, Carlson-Dakes, Hughes, 
Kwekkeboom, & Donovan, 1998) was used to capture side effects of analgesics at 
baseline (T1). The MSEC identifies the presence, type, and severity of eight analgesic 
side effects during the prior week (0-10 scale from no severity to extreme severity). Side 
effects include constipation, drowsiness, nausea, vomiting, confusion, dry mouth, upset 
stomach, and itching. The MSEC has excellent internal consistency reliability with 
Cronbach α of .81 (Ward et al., 1998) and was .79 in this study. 
 Pain Severity and Pain Impact 
 Baseline measurement of both pain severity and pain impact were elicited at 
baseline with the Brief Pain Inventory (BPI) (Cleeland & Ryan, 1994). The BPI measures 
worst, least, and average pain scores over the week prior to assessment, as well as current 
pain level (0-10 scale from no pain to pain as bad as you can imagine). The BPI has been 
well-documented in research with cancer patients and demonstrates internal consistency 
reliability using Cronbach α ranging from .77 to .91 (Anderson et al., 2000; Cleeland et 
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al., 1994; Cleeland & Ryan, 1994; Meghani & Keane, 2007; Meghani et al., 2015; Rhee 
et al., 2012; Yeager et al., 2019). In this study, the reliability coefficient was .90. 
 Pain Management Index 
The Pain Management Index (PMI) was calculated for each patient according to 
the WHO (1986, 1996, 2018) guidelines for cancer pain treatment. The PMI is reflective 
of the relationship between the most potent analgesic prescribed and the patient’s self-
reported pain level. The PMI is calculated by taking the most potent prescribed analgesic 
and subtracting the patient’s self-reported pain level (classified using the Brief Pain 
Inventory as mild, moderate, or severe). Insufficient analgesic prescription strength 
relative to a patient’s self-reported pain level is typically demonstrated by a negative PMI 
score. 
Social Support Questionnaire 
 A six-item abbreviated version of the 27-item Social Support Questionnaire 
(Sarason, Levine, Basham, & Sarason, 1983) was used to identify patients’ level of social 
support and satisfaction with perceived support. Patients first identify the individuals in 
their life who provide social support and then rate the level of satisfaction level they 
experience with the support.  
Demographic and Illness-Related Variables 
 Demographic data were self-reported and included age, gender, self-identified 
race, marital status, education level, income, and health insurance type. A number of 
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variables related to illness were gathered through medical chart review including cancer 
type and stage, time since cancer diagnosis, past history of depression or substance abuse, 
and comorbidities used to calculate a Charlson comorbidity score (Charlson, Pompei, 
Ales, & MacKenzie, 1987).   
Statistical Analysis 
 All analyses for the current study were performed using the Stata/IC 15 platform. 
Descriptive statistics were generated for relevant sociodemographic and clinical 
variables. Means and standard deviations are provided for continuous variables and 
frequencies and percentages for categorical variables. 
General linear modeling was the primary statistical method used to achieve the 
study aim. Prior to building the regression model, bivariate analyses between predictor 
variables and the outcome adherence variable were assessed. Relevant sociodemographic 
and clinical variables significant at the bivariate level (p < .20) at T1 were considered as 
potential predictors of MEMS® dose adherence at T2. Two models were then 
constructed. 
For model 1, variables that met the p < .20 criteria, in addition to theoretically 
salient variables (e.g., history of substance abuse and presence of depression), were used 
to construct a preliminary prediction model employing a backward elimination method. 
The backwards elimination method is useful in evaluating the value of each potential 
predictor when studying a phenomenon that may be influenced by a number of 
confounders (Cohen & Cohen, 1983). After starting with all individual potential 
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predictors in the preliminary model, we then subsequently removed any variable that 
improved the model most significantly by its deletion. This elimination process included 
theoretical variables. We repeated this process until no additional model improvement 
was possible and all predictors were significant at the α = .05 level.  
In model 2, the same theoretically salient variables used in the first model were 
included. The clusters variable was then entered as a dichotomous categorical variable 
with cluster 1 and cluster 2 as levels to evaluate the impact of analgesic treatment beliefs 
on analgesic adherence by observing any change in the R-squared value. The clusters 
variable was the primary variable of interest and, therefore, was retained in the backward 
elimination process, regardless of statistical significance. This is consistent with the 
statistical convention to maintain insignificant findings in a final model when the 
explanatory variable is of primary interest or there is a specific hypothesis about a given 
variable (Grace-Martin, 2020; Heinze & Dunkler, 2017).  
Variance inflation factors suggested low levels of multicollinearity among 
predictors in both models one and two (1.49 and 1.43 respectively) (Chatterjee & Yilmaz, 
1992). Using studentized residuals during residual analysis, no observations fell beyond 
the criteria of concern (x > 3, x < -3). The outcome variable was assessed using 
histograms and Shapiro-Wilk test (0.87), neither of which showed concerns with 
violations of normality assumptions. In addition, MEMS® dose adherence was subjected 
to a sensitivity analysis to remove two observations significantly greater than 100% 





 Subjects (N=207) had a mean age of 53.8 years (SD=11.1), less than half 
identified as African-American (41.5%), and most were female (56.5%). The majority 
rated their general health as “good” (30.4%) or ”fair” (37.2%); less than 5% of the 
sample rated their general health as “excellent” at baseline. Most patients denied a history 
of substance abuse (83.1%) or current presence of depression (58%). Table 1 shows 
subjects by demographic and illness variables for the entire sample and by cluster; no 
significant differences between clusters were identified. Table 2 shows the belief clusters 
identified in our prior study (Rosa et al., 2019).  
 Examining the sample by analgesic and pain management variables (Table 3) 
shows that patients used a total of roughly 2.1 analgesics to treat their pain, with the vast 
majority (80.2%) prescribed a strong opioid (WHO step 3). Their average least to worst 
pain scores over the previous week ranged from 3.4 to 6.9 out of 10 respectively. Clusters 
1 and 2 differed significantly in how they rated severity of side effects (p=0.043). There 
were no statistically relevant differences between clusters in terms of other variables, 
such as pain management index, pain interference, or the number of self-identified 
barriers to analgesic use.  
 MEMS Analgesic Adherence 
 The clusters variable based on analgesic beliefs was not found to be statistically 
significant at the bivariate level (p=0.709) but was included in all modeling computation 
as the primary variable of interest. A number of relevant sociodemographic and clinical 
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variables met inclusion criteria for linear modeling (p < .20) (Table 4). Both average and 
worst pain scores were tested for potential inclusion; the average pain score (p=0.004) 
was selected due to a higher level of significance.  
 The first model showed that race, side effects, most potent analgesia prescribed, 
pain relief with analgesics, and the duration of disease were all significant at the α < .05 
level (Table 5). This analysis was initially generated without the cluster variable to 
evaluate the relationship between other salient correlates and the MEMS variable in the 
absence of cluster influence. Variables such as average pain score, history of substance 
abuse, presence of depression, income, age, pain management index, and insurance type 
were excluded throughout the elimination process. Approximately 21% of objective 
analgesic adherence variance using MEMS was explained by the final model (r2 = 0.207).  
 The clusters variable was entered to Model 2 and, following the backward 
elimination method, the same variables were identified as statistically significant (Table 
6). Although the clusters variable was nonsignificant (p = 0.545), it remained in the 
model as the primary variable of interest. Similar to the first model, these predictors 
accounted for 21% of variance observed in the analgesic adherence variable (r2 = 0.208).  
Discussion 
 
 We sought to determine if unique clusters based on patients analgesic treatment 
beliefs predicted analgesic adherence behaviors objectively monitored using electronic 
monitoring. We found that analgesic belief clusters were not statistically associated with 
adherence in this adjusted analysis. However, other clinically relevant factors such as 
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race, side effects, most potent analgesia prescribed, pain relief with analgesics, and the 
duration of disease significantly predicted objective adherence to analgesics for cancer 
pain. The findings raise important questions about the role of patient beliefs, 
sociodemographic background, and clinical history in relation to adherence behaviors in 
the setting of cancer pain.  
While analgesic treatment beliefs, preferences, and concerns of patients and 
families have been previously associated with analgesic use (Liang et al., 2013; Meghani 
& Knafl, 2017; Meghani et al., 2015; Rhee et al., 2012; Simone et al., 2012), our findings 
in this study show that beliefs ultimately do not explain patients’ objective analgesic 
taking behaviors. For example, we found that in an adjusted analysis accounting for other 
confounders, it is the experiential variables (e.g., race, side effects, most potent analgesia 
prescribed, pain relief with analgesics, duration of disease) that matter most in predicting 
adherence. These experiential variables have all been substantiated by extant literature as 
having an impact on adherence behaviors (Manzano et al., 2014; Meghani et al., 2013; 
Meghani et al., 2014; Meghani & Knafl, 2017; Meghani et al., 2015). These covariates 
are clinically relevant and appear to be interrelated. For instance, stronger opioids may 
lead to improved pain relief but may also exacerbate the severity of side effects. 
Additionally, stronger opioids (e.g. WHO step 3) may also relate to more advanced 
cancer diagnosis and increased adherence (Meghani et al., 2015; Oldenmenger, Sillevis 
Smitt, de Raaf, & van der Rijt, 2017). 
Race was the most significant among the covariates within the model, which 
supports previous research findings. Studies exploring race related to analgesic adherence 
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have demonstrated that African-American and White patients differ on the beliefs and 
concerns most important to them. For instance, past analysis of this current sample shows 
that African-Americans are most concerned about severity of side-effects, which is 
positively correlated with increased nonadherence behaviors in this population (Meghani 
et al., 2013; Meghani & Knafl, 2017; Meghani et al., 2015). White patients in the same 
sample tended to make trade-offs based on the amount of pain relief afforded by 
analgesic treatment. African-Americans in previous findings were less likely to be 
prescribed long-acting WHO step 3 opioids than Whites (Meghani & Knafl, 2017).  
Importantly, severity of pain was not included in either model 1 or 2 based on our 
analytical exclusion criteria but remains clinically significant. More potent analgesia may 
serve as a proxy for pain severity. In addition, disease duration likely serves as an indirect 
proxy for pain severity as it may imply more serious pain symptoms requiring higher 
potency analgesics. Of note, although theoretically salient, history of substance abuse 
also was not a statistically significant variable in the final regression models. This may be 
due to the fact that the vast majority of patients in the sample did not endorse a history of 
prior substance abuse.  
There are several limitations of this study. First, the analgesic belief clusters used 
as the primary variable of interest are not exhaustive of all potential patient beliefs. 
However, we used a well-substantiated tool for eliciting pain management and analgesic 
concerns in the cancer pain literature. Future research may aim to elicit additional 
relevant beliefs as they relate to analgesic use for cancer pain or new concerns garnering 
salience in the current national context. Second, clusters based on analgesic beliefs were 
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not statistically significant. Nonetheless our research supports further exploration of the 
extent to which patient beliefs versus other clinical and sociodemographic variables 
interact with these beliefs to impact cancer pain outcomes. Third, while a two-cluster 
model was previously identified (Rosa et al., 2019), there are likely multiple groups of 
patients that prioritize their beliefs differently. We anticipate the findings of this current 
study are merely a starting point for identifying how variant patient priorities inform 
analgesic adherence in patient populations. Fourth, while the age of the data is a concern, 
the parent study collected data at the peak of the first wave of opioid epidemic. Thus, we 
expect that the unique longitudinal dataset focusing on patients’ analgesic taking in the 
context of opioid crisis has relevance in the current context. Last, while these findings 
support previous research findings about predictors of adherence, we cannot generalize 
beyond this sample.  
Implications for Nursing 
 
Nurses should observe for changing trends in opioid prescribing practices as they 
relate to analgesic adherence behaviors. While certain guidelines specific for cancer pain 
management continue to recommend opioids based on patients’ subjective  pain report 
and a combination of short- and long-acting opioids for optimal pain control (NCCN, 
2019; WHO, 2018), the broader national conversation on opioid prescribing is turning 
toward more modest analgesic treatment focused on short-acting opioid use (Dowell et 
al., 2016). Our findings, in conjunction with the national opioid epidemic discourse, 
suggest a needed re-evaluation of interventions geared toward improving adherence for 
cancer pain. As suggested by this sample and a number of other studies (Meghani & 
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Bruner, 2013; Meghani et al., 2014; Oldenmenger et al., 2017; Rhee et al., 2012), there 
are clearly subsets of patients that continue to require around-the-clock analgesic 
prescription to effectively manage pain. Of concern, previous data highlight that patients 
are not using analgesics for cancer pain on a scheduled basis.  For example, previous 
findings related to this current sample showed only 69% of patients (n=207) were 
adherent to WHO step 3 short-acting opioids and roughly 74% were adherent to long-
acting opioids (Meghani & Knafl, 2017). Although there have been substantial efforts to 
tailor education for patients to address analgesic beliefs and barriers, systematic reviews 
show that these interventions neither improve analgesic adherence nor associated pain 
outcomes for cancer pain (Bennett, Bagnall, & Jose Closs, 2009; Oldenmenger et al., 
2018; Oldenmenger, Sillevis Smitt, van Dooren, Stoter, & van der Rijt, 2009). The 
evidence suggests that continued focus on evaluating key clinical variables, such as 
analgesic side-effects and pain report, as well as other sociodemographic and economic 
factors like race, income, and health literacy may be central to improved outcomes 
associated with cancer pain (Meghani & Bruner, 2013; S.H. Meghani et al., 2013; 
Meghani et al., 2014; Meghani & Knafl, 2017; Meghani et al., 2015).  
Conclusion 
 
 This study shows that patient clusters based on analgesic treatment beliefs do not 
impact adherence behaviors significantly. However, we found clinical variables that 
speak to the experience of cancer pain and pain treatment are most relevant to analgesic 
adherence. Our findings affirm extant literature and support ongoing evaluation to 
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address, through clinical interventions, the key experiential variables that influence pain 
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Table 1. Demographic and Illness Variables for Sample and by Analgesic Treatment  












Age, y, mean (SD) 53.8 (11.1) 54.2 (12.5) 53.7 (10.7) 0.798 
Time since cancer diagnosis, mo, mean 
(SD) 
36.7 (35.5) 30.5 (29.4) 38.9 (37.2) 0.138 
Charlson Comorbidity Index, mean 
(SD) 
4.3 (2.6) 4.4 (2.3) 4.3 (2.8) 0.725 
Health literacy, mean (SD) 13.1 (2.6) 13.3 (2.7) 13.0 (2.6) 0.413 
Social support, mean (SD) 3.7 (2.1) 4.1 (2.3) 3.6 (2.0) 0.102 
Physical health not good, within past 
30 days, mean (SD) 
14.7 (10.7) 15.7 (11.3) 14.4 (10.5) 0.439 
Mental health not good, within past 30 
days, mean (SD) 
9.5 (10.7) 8.3 (10.1) 9.9 (10.9) 0.333 
General health 
    Excellent 
    Very good 
    Good 
    Fair 





















    Male 






















    White 121 (58.5) 30 (56.6) 91 (59.1) 
Marital status 
    Married 
    Separated/divorced/widowed 















    Elementary 
    High School 
    College/trade school 


















    Full-time outside home 
    Part-time outside home 
    Full-time at home 
    Part-time at home 
    Retired  
    Unemployed 




























    < 30,000 
    30,000-50,000 
    50,000-70,000 
    70,000-90,000 


























Insurance type    
    Private 
    Medicare 
    Medicaid 
    Multiple  





















    Lung 
    Breast 
    Gastrointestinal 
    Genitourinary/reproductive 
    Multiple myeloma 
























    I 
    II 
    III 
    IV 





















History of substance abuse 
    Yes 











Presence of depression 
    Yes 













NOTE: Values are n (%) unless otherwise noted.  
*P-values are based on t-tests for continuous variables and χ2 for categorical 
variables.Clusters 1 and 2 are based on previous findings as discussed in text.  

























Table 2. Analgesic Treatment Belief Clusters (Rosa et al., 2019).  
Side Effects Cluster Rank 
Order 
Need it Later Cluster 
 Pain meds keep you from 
knowing what is going on in 
your body.   
 
1 
 Pain meds keep you from 
knowing what is going on in your 
body.   
 It is easier to deal with the pain 
than the side effects that come 
from the pain meds.  
 
2 
 If you use pain medicine now, it 
won’t work when you need it 
later.  
 It is important to be strong by 
not talking about pain.  
 
3 
 Pain meds weaken the immune 
system. 
 Many people with cancer get 
addicted to pain meds.  
 
4 
 Many people with cancer get 
addicted to pain meds.  
 If you use pain medicine now, it 




 Cancer pain cannot be relieved 
with medications.  
 If I talk about pain, people will 
think I’m a complainer.  
 
6 
 If doctors have to concentrate on 
pain they won’t focus on treating 
the cancer.  




 It is easier to deal with the pain 
than the side effects that come 
from the pain meds.  
 Cancer pain cannot be relieved   It is important to be strong by not 
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with medications.  8 talking about pain.  
 Pain meds make you say or do 
embarrassing things.  
 
9 
 If I talk about pain, people will 
think I’m a complainer.  
 If doctors have to concentrate on 
pain they won’t focus on 
treating the cancer.  
 
10 
 Pain meds make you say or do 
embarrassing things.  
 
*Beliefs were based on the Barriers-Questionnaire-II (BQ-II) domains (see methods) and 






















Index analgesic, n (%) 
    WHO step 1 
    WHO step 2 














Pain management index (-2 - +3) 0.5 (1.0) 0.5 (0.8) 0.6 (1.0) 0.687 
Worst pain (BPI, 0-10) 6.9 (2.4) 7.1 (2) 6.8 (2.4) 0.265 
Least pain (BPI, 0-10) 3.4 (2.0) 3.4 (1.9) 3.4 (2.0) 0.533 
Average pain (BPI, 0-10) 4.9 (2.1) 5.0 (2.0) 4.9 (2.1) 0.397 
Pain interference (BPI, 0-10) 35.2 (15.9) 36.2 (15.8) 34.9 (16.0) 0.309 
Severity of side effects (MSEC, 0-
80) 
25.2 (15.0) 28.8 (15.6) 24.0 (14.6) 0.043 
Barriers Questionnaire (BQ-II, 0-
135) 
66.8 (20) 63.7 (19.4) 67.8 (20.2) 0.200 
Total number of analgesics 
prescribed (excluding co-
analgesics) 
2.1 (0.8) 2.2 (1.0) 2.0 (0.7) 0.155 
Total number of co-analgesics 
prescribed 
0.2 (0.5) 0.3 (0.6) 0.2 (0.5) 0.322 
% overall adherence 65.1 (34.5) 63.6 (33.9) 65.6 (34.9) 0.645 
NOTE: Values are mean (SD) unless otherwise noted.  
Abbreviations: WHO, World Health Organization; BPI, Brief Pain Inventory; MSEC,  
Medication Side-Effects Checklist; BQ, Barriers Questionnaire  
*P-values are based on t-tests for continuous variables and χ2 for categorical variables. 
Clusters 1 and 2 are based on previous findings cited earlier.  
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Table 4. Bivariate Results of Predictors of MEMS® Adherence Included in Linear  
   Modeling. 





Private insurance  
(missing data n=203) 
0.003 
Duration of disease 0.010 
Side effects magnitude 0.140 
Average pain (last week) 0.004 
Most potent analgesic 0.002 
Pain management index 0.001 
Pain relief with analgesics 0.003 
Presence of depression 0.329 
History of substance abuse 0.260 
 
*P-values are based on bivariate analysis of variance (ANOVA) for all variables. 
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Table 5. Predictors of Objective Analgesic Adherence Excluding Clusters Variable. 
 
Variable F Statistic P-Value* 
Race 19.27 0.000 
Side effects 4.22 0.041 
Most potent analgesia 3.45 0.034 
Pain relief with analgesics 7.69 0.006 
Duration of disease 9.05 0.003 
 



















Table 6. Predictors of Objective Analgesic Adherence Including Clusters Variable.   
 
Variable F Statistic P-Value* 
Clusters 0.37 0.545 
Race 19.27 0.000 
Side effects 4.22 0.041 
Most potent analgesia 3.45 0.034 
Pain relief with analgesics 7.69 0.006 
Duration of disease 9.05 0.003 
 









































Summary of Integrated Findings and Discussion 
 Through literature review, conceptual and empirical analyses, and iterative 
syntheses of findings, this dissertation explored patients’ analgesic treatment beliefs for 
cancer pain and the association of those beliefs with objective analgesic adherence 
behaviors. This timely focus is critical to better understanding how patient beliefs, 
analgesic adherence measures, and cancer pain management intersect in the context of 
the opioid epidemic. Importantly, the significance of this work is rooted in the high 
prevalence of moderate to severe cancer pain (Shi et al., 2011; van den Beuken-van 
Everdingen, Hochstenbach, Joosten, Tjan-Heijnen, & Janssen, 2016), as well as the 
policy and scientific initiatives that are impacting opioid monitoring and prescribing 
practices, as well as pain relief guidelines across settings (Christie et al., 2017; National 
Academies of Sciences, 2017, 2018; National Academy of Medicine, 2017; U.S. 
Department of Health and Human Services, 2019).  
Despite cancer pain guidelines that identify World Health Organization (WHO) 
step 3 opioids (e.g., morphine, hydromorphone) as the foundation of moderate to severe 
cancer pain treatment plans (National Comprehensive Cancer Network [NCCN], 2019; 
Paice et al., 2016; WHO, 2018), other recommendations discourage the use of such 
opioids for cancer survivors or patients not receiving palliative or end-of-life care 
(Dowell, Haegerich, & Chou, 2016). Discrepancies in these guidelines have contributed 
to oncology clinicians’ uncertainty about opioid prescribing and use, as well as potential 
risks to patient safety given differing expert recommendations (Meghani & Vapiwala, 
2018; Ranapurwala, Naumann, Austin, Dasgupta, & Marshall, 2018). The interplay of 
160 
 
divergent pain management guidelines, high cancer pain burdens, and the clinical 
implications of the opioid epidemic - such as pre-authorization insurance requirements 
for analgesics and more conservative prescribing practices – require more research that 
elucidates the factors influencing patients’ analgesic taking behaviors (Johnson et al., 
2018; Lamar, 2018; National Academies of Sciences, 2017).   
 There has been much described throughout the prior chapters about the prescriber 
and healthcare system aspects of analgesic use. However, there continues to be an 
empirical gap in understanding patients’ beliefs about analgesic treatments for cancer 
pain, and especially, how those beliefs inform their objective analgesic adherence. Three 
studies were conducted to achieve the overall aim. The first was a concept analysis 
(chapter 2) that provided a basis for later data analyses and a lens through which to 
consider study findings. Subsequently, in chapters 3 and 4, we quantitatively explored the 
phenomenon of interest by analyzing the significance of patients’ cancer pain treatment 
beliefs and then determining the correlation of those beliefs with their analgesic 
adherence behaviors. The purpose of this chapter is to articulate overall conclusions 
through a review of chapter aims and synthesis of key findings, implications for future 
practice, education, research, and policy domains, and the major strengths and limitations 
of the dissertation.   
Review of Chapter Aims and Synthesis of Key Findings 
 
In chapter 1, we provided an overview and background of the phenomenon of 
analgesic nonadherence, particularly in the context of the opioid epidemic. Additionally, 
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we made explicit the innovation of this current work and identified the relevant sample 
and variables from the parent study, as well as the methods, to be used throughout the 
dissertation. In this first section, the salience of additional scientific inquiry pertaining to 
analgesic adherence for cancer pain was emphasized, including a substantive literature 
gap and critical need to better understand the patient perspective related to analgesic use 
for cancer pain.  
In chapter 2 (Rosa, Riegel, Ulrich, & Meghani, 2020), a concept analysis of 
analgesic nonadherence for cancer pain in a time of opioid crisis using the Walker and 
Avant (2019) method was presented. The purpose was to clarify the concept of analgesic 
nonadherence for cancer pain and qualify its utility in the context of the epidemic. To our 
knowledge, this was the first conceptual analysis of analgesic nonadherence among this 
population and was a vital step to clarifying how the concept is employed and measured 
in the literature, and the impact of differing analgesic adherence behaviors on patients 
and cancer pain outcomes.   
 Of note, we found that few studies made the link between analgesic nonadherence 
and patient outcomes. For example, only one study identified inconsistent opioid 
adherence for cancer pain as the strongest predictor of hospitalization (Meghani & Knafl, 
2016). In addition, increased nonadherence due to patient or family hesitancy to use 
analgesics as prescribed was correlated with increased pain severity and negative 
consequences on physical and social function that decreased overall quality of life (Lee et 
al., 2015; Manzano, Ziegler, & Bennett, 2014). In fact, the lack of empirical data 
alongside the widespread implications of the opioid crisis and dissonance among pain 
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management guidelines created a lack of clarity about the utility of analgesic 
nonadherence as a concept in the field.  
 Ultimately, the concept analysis provided a rationale for the additional studies in 
chapters 3 and 4. The synthesis of the literature created more questions than answers. 
First, the specific elements that constituted optimal adherence behaviors related to 
prescribed analgesics for cancer pain were unclear. Both a lack of evidence in 
conjunction with the practice and policy changes discussed above made evident the need 
for additional empirical findings that elucidated the phenomenon of analgesic 
nonadherence for the cancer patient population. Second, although the national 
sociopolitical dialogue has focused on how to balance social welfare with individual pain 
alleviation in this time of opioid crisis (National Academies of Sciences, 2017), more 
data was needed to better understand what factors influence patients’ adherence 
behaviors. Third, the disagreement between opioid prescribing guidelines, as well as the 
lack of empirical evidence to support those guidelines, is  a barrier to understanding 
analgesic nonadherence for cancer pain. For example, as argued by Meghani & Vapiwala 
(2018), the Center for Disease Control (CDC) guidelines discourage the concomitant use 
of extended- and immediate-release opioids (Dowell et al., 2016) while a number of 
national organizations promote this multimodal approach for effective pain relief 
(NCCN, 2019; Paice et al., 2016; WHO, 2018). Analgesic nonadherence in this time of 
the CDC guidelines – and in the absence of high-quality empirical data to support these 
guidelines - complicates clarity around prescribing, monitoring, and effectiveness. 
Fourth, many studies used various surveys and instruments to measure adherence rates 
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but there was a substantial gap related to the underlying patient decision-making 
processes that inform analgesic taking behaviors. This gave validity to the need to further 
explore the decision-making utilities employed by patients when thinking about their 
analgesic medications to treat their cancer pain.  
In chapter 3 (Rosa, Chittams, Riegel, Ulrich, & Meghani, 2019), we briefly 
discussed how many patients with cancer pain deviate from their prescribed analgesic 
regimens for a host of reasons (e.g., severity of side effects, concern about dependence or 
addiction, family or caregiver hesitancy to use analgesics), including their analgesic 
treatment beliefs (Manzano et al., 2014; Meghani & Bruner, 2013; Meghani, Chittams, 
Hanlon, & Curry, 2013; Meghani, Thompson, Chittams, Bruner, & Riegel, 2015; Rhee, 
Kim, & Kim, 2012; Schumacher et al., 2014b; Simone, Vapiwala, Hampshire, & Metz, 
2012). Specifically, the aims of this study were to (1) elicit the trade-offs patients make 
based on their beliefs about analgesic use; (2) rank utilities (importance scores) using a 
maximum difference (MaxDiff) scaling-derived k means cluster analysis to evaluate how 
beliefs differed between groups; and (3) describe clusters by comparing key 
sociodemographic and clinical variables. MaxDiff - a consumer preference tool rooted in 
random utility theory (Thurstone, 1927) - is underutilized in the social sciences literature 
and provided us with an innovative empirical approach to understanding how groups of 
patients prioritize their beliefs around analgesic treatment for cancer pain, based on a 
widely used barriers to cancer pain management validated instrument (Ward et al., 1993).  
A primary finding of chapter 3 was that patients’ beliefs are significant in their 
choices when thinking about pain medicines. This finding aligns with extant literature 
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showing an association between analgesic beliefs and analgesic adherence behaviors 
(Liang et al., 2013; Meghani & Bruner, 2013; Torresan et al., 2015; Valeberg, 
Miaskowski, Paul, & Rustoen, 2016). The analysis showed that trade-offs based on 
particular beliefs about cancer pain management strongly effected choices about 
analgesic use.  
For instance, patients across the sample were about 24% more likely to make 
trade-offs about analgesic medications based on the belief that “pain meds keep you from 
knowing what is going on in your body”. In other words, “knowing body” was identified 
as the most important belief and patients were more likely to make choices based on this 
belief over other beliefs. In fact, the belief of “knowing body” may be a key aspect of 
understanding primary concerns regarding analgesic taking behaviors among patients 
with cancer who experience pain. Researchers have found that many patients link the 
presence of pain with disease status and, therefore, the need to “know their body” is 
crucial (Rau et al., 2017). Furthermore, patients who have shown intentionally 
nonadherent behaviors (e.g., stop taking analgesics when they feel better or worse) agree 
with the belief of “knowing body” (Meghani & Bruner, 2013). This suggests that the 
desire to “know body” may often be prioritized over adherence to prescribed analgesic 
regimens or the need to mitigate pain symptoms. Additional studies show that some 
patients deny pain as a symptom of disease (Torresan et al., 2015) and others believe 
opioids should only be used in advanced disease stages (Liang et al., 2013), supporting 
the idea that analgesics may only be more readily utilized when patients have a reliable 
understanding of what is happening in their bodies.  
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Given the urgency surrounding the national opioid epidemic discourse, it was 
somewhat surprising to see that patients across the sample in our MaxDiff study ranked 
the belief that “many people with cancer get addicted to meds” as only moderately 
important (ranked fourth out of ten beliefs). Taking into consideration that these data 
were collected during the second wave of the opioid crisis in the United States (2009-
2011), we originally anticipated that subjects would have given more weight to this 
belief. Some previous studies do acknowledge patient concern about physiological 
dependence or addiction to opioids as a decision-making factor affecting analgesic use 
(Jacobsen et al., 2014; Liang et al., 2013; Simone et al., 2012). However, our findings 
support previous research that addiction concerns do not ultimately explain either 
objective or subjective measures of analgesic adherence in the cancer patient population 
(Meghani et al., 2015; Rhee et al., 2012). If the parent study were to be replicated today, 
we assume addiction concerns might generate a higher utility given the consequences of 
the third wave of the epidemic that started in 2013 (CDC, 2018) related to synthetic 
opioid overdose deaths. This would support other recent findings that show addiction was 
the second top concern among ambulatory patients undergoing active cancer treatment 
(Meghani et al., 2020). The MaxDiff trade-off findings highlight the need to better 
understand how patients’ preferences and beliefs related to analgesic use may differ from 
national research and policy initiatives focused on more conservative opioid prescribing 
practices to mitigate addiction risk. 
 Following the initial MaxDiff operation, a cluster analysis identified two distinct 
clusters of patients based on analgesic treatment beliefs, representing unique decision-
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making utilities. A primary takeaway from this analysis shows that there is significant 
variation in how clusters of patients prioritize their beliefs related to cancer pain 
treatment, and this variation likely reflects differences in individual beliefs and the utility 
of those beliefs when thinking about analgesic use. The only sociodemographic or 
clinical variable that differed significantly by cluster was the belief that “it is easier to 
deal with the pain than the side effects that come from the pain meds”. This outcome 
aligns with empirical data associating an increased number of side effects and severity of 
those side effects with an increase in nonadherence to analgesics (Manzano et al., 2014; 
Meghani & Bruner, 2013; Meghani et al., 2014). Our findings suggest that the utility of 
the “side effects” belief may be salient concern for some patients with cancer pain and 
not for others. Thus, it appears that patients prioritize beliefs around analgesic use quite 
differently. In fact, the cluster analysis showed significant variation between how the two 
clusters prioritized analgesic treatment beliefs. This variation likely reflects individual 
belief differences and the weight patients give to those beliefs regarding analgesic use 
trade-offs. This outcome is consistent with researchers who found more than a quarter of 
patients traded-off on analgesic decisions based on a number of differing concerns, 
including the type and the severity of side effects (Meghani & Knafl, 2017).  
 Subjects in cluster 2 ranked the belief, “If you use pain medicine now, it won’t 
work when you need it later,” as the second rated utility. Patients have previously noted 
concern that if opioids are used in earlier stage disease than their analgesic effect may be 
less potent later on as symptoms worsen (Liang et al., 2013). This worry about tolerance 
to pain medication is likely an ongoing concern for patients with moderate to severe 
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chronic cancer pain who require analgesic treatment over time. Findings show that pain 
continues to be one of the top three most troubling symptoms at one-year post-diagnosis 
and cancer survivors tend to report levels of pain similar to those undergoing active 
treatment (Shi et al., 2011). A number of utility scores were ranked quite low among both 
clusters, including, “Won’t focus on cancer,” “Be strong,” “Say embarrassing things,” 
and “Complainer.” These low-ranking utilities reflect a prior study showing that for 
patients with cancer pain, these beliefs are less important than “Knowing body” or “Harm 
immune system” (Valeberg et al., 2016).   
The analysis conducted in chapter 4 explored whether the analgesic treatment 
belief clusters from the previous chapter predicted objective analgesic adherence 
behaviors using an electronic medication monitoring system known as the Medication 
Event Monitoring System (MEMS®; MVW Switzerland Ltd., Sion, Switzerland). A 
general linear modeling was used with a backward elimination approach to identify 
significant correlates of MEMS® adherence data (Cohen & Cohen, 1983). Relevant 
confounders and theoretically salient variables were accounted for throughout the 
analysis to determine the significance of sociodemographic (e.g., race), clinical (e.g., 
duration of disease), and pain-related (e.g., most potent analgesia prescribed and pain 
relief with analgesics) explanatory factors.  
 Prior to conducting the chapter 4 analysis, we hypothesized that analgesic 
treatment belief clusters would be predictive of objective analgesic adherence. However, 
they were not statistically significant in our linear modeling results. Chapter 3 findings 
suggested that analgesic treatment beliefs weigh significantly in the choices patients 
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articulated regarding analgesic use and there are unique subgroups of patients based on 
these analgesic beliefs. However, our chapter 4 outcomes showed that beliefs did not 
predict objective adherence behaviors. In fact, in an adjusted analysis when accounting 
for relevant confounders, it was ultimately experiential variables that drive their objective 
analgesic use. For example, multiple predictors of adherence were noted and support 
findings from prior studies, including race, side effect severity, the type of analgesia 
prescribed, pain relief from analgesics, and the duration of disease (Manzano et al., 2014; 
Meghani et al., 2013; Meghani et al., 2014; Meghani & Knafl, 2017; Meghani et al., 
2015). These variables explained 21% of the variance in electronically-monitored 
analgesic adherence at T2.  
Among these factors, race was the most significant predictor in the model and has 
consistently been shown to impact adherence behaviors. Our findings reflect those of 
other researchers who have shown, for example, that African-Americans are less likely to 
be prescribed an extended-release WHO step 3 opioid for cancer pain management than 
Whites and also have increased concern about analgesics side-effect severity, correlating 
with increased nonadherence behaviors (Meghani & Bruner, 2013; Meghani & Knafl, 
2017; Meghani et al., 2015). The remaining covariates are clinically relevant. In Chapter 
4 we give the example of how these variables relate to one another and adherence 
behaviors: Stronger opioids may lead to improved pain relief but may also exacerbate the 
severity of side effects. Additionally, stronger opioids (e.g. WHO step 3) may also relate 
to more advanced cancer diagnosis and increased adherence (Meghani et al., 2015; 
Oldenmenger, Sillevis Smitt, de Raaf, & van der Rijt, 2017).  
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 It is important to note the clinical relevance of pain severity in the analgesic 
adherence and cancer pain research. Although pain severity was not statistically 
significant in our linear models based on our analytical exclusion criteria, a number of the 
variables that were predictive of adherence may serve as proxies for pain severity. For 
instance, more potent analgesia and duration of disease, both of which indirectly imply 
greater levels of pain and potentially disease progression. In addition, history of 
substance abuse was not found to be significant in our modeling, however, a majority of 
subjects in this sample did not report history of substance abuse.  
A key question raised in chapter 4 by these findings is: How useful is the concept 
of analgesic adherence for cancer pain amid evolving prescribing guidelines secondary to 
the opioid addiction epidemic? As guidelines continue to emphasize the utilization of 
immediate-release, as-needed analgesics for pain management, further research and 
scholarly dialogue should address the validity of measuring adherence behaviors. 
Adherence - as a measure - is only effective for tracking patient consumption of 
scheduled, extended-release opioids in this clinical scenario. To this end, our overall 
findings support a need to re-evaluate how we measure and understand analgesic use for 
this population. The current literature suggests that patients have low to moderate 
analgesic adherence rates at best and significant variability in using prescribed analgesics 
(Meghani & Knafl, 2017). Furthermore, several varied patient education interventions 
(e.g., booklets, video/computer programs, face-to-face instruction) improve pain 
outcomes only for a small percentage of patients, likely due to their inability to 
individualize approaches to alter beliefs or concerns (Bennett, Bagnall, & Jose Closs, 
170 
 
2009; Oldenmenger et al., 2018; Oldenmenger, Sillevis Smitt, van Dooren, Stoter, & van 
der Rijt, 2009). However, there will continue to be a subset of patients who will require 
around-the-clock analgesics for the relief of moderate or severe pain where adherence 
measurement would continue to remain clinically relevant (Meghani & Bruner, 2013; 
Meghani et al., 2014; Oldenmenger et al., 2017; Rhee et al., 2012). 
Better understanding self-management approaches of patients with cancer pain 
may be integral to improving cancer pain outcomes and understanding underlying 
analgesic taking behaviors. Of note, researchers have found there are potentially unsafe 
self-management strategies employed by cancer pain patients that require timely 
attention, such as self-tapering opioids, cutting pills, substituting extended-release opioids 
for “as needed” relief, and using over-the-counter and illicit drugs to mitigate or avoid 
opioids (Meghani et al., 2020). Ultimately, the findings in chapter 4 support continuing to 
evaluate key structural and clinical variables, such as analgesic side-effects, pain reports, 
and other sociodemographic and economic factors, such as race, is likely central to 
improving cancer pain outcomes (Meghani & Bruner, 2013; Meghani et al., 2013; 
Meghani et al., 2014; Meghani & Knafl, 2017; Meghani et al., 2015; Yeager et al., 2019). 
Considering analgesic adherence from a broader perspective, integrating beliefs, self-
management practices, clinically relevant confounders, and the experiential variables we 
identified as significant is likely to improve pain outcomes and provide a more in-depth 






There are limited empirical data on long-term opioid use (e.g., more than three 
months) to inform best practices, leading to conflicting opioid prescribing 
recommendations among guidelines (Dowell et al., 2016; Meghani & Vapiwala, 2018; 
NCCN, 2019; Paice et al., 2016; WHO, 2018). This has led to concerns about how to best 
prescribe opioids and other analgesics for cancer pain (e.g., immediate- vs. extended-
release, around-the-clock vs. as needed). One of the most relevant questions to emerge 
from this work is: What is the role of opioid ‘adherence’ in the era of the CDC guidelines 
(Dowell et al., 2016) and national concerns with opioid crisis?  
Organizational and policy responses are underway to address some of the 
challenges secondary to the rapid and, at times, misappropriated uptake of the CDC 
guidelines (Dowell, Haegerich, & Chou, 2019), such as sudden discontinuation or taper 
of analgesic dosing or barriers to multimodal pain care access. Continued education for 
prescribers and policy makers that reflects the accuracy of the CDC prescribing 
guidelines in their entirety is imperative to ensure responsible opioid dosing and planning 
(Kroenke et al., 2019). When considering the findings from this dissertation amid the 
opioid crisis, we must evaluate the resources and energy being used to advance the 
science of analgesic adherence for cancer pain given the evolution of the concept in 
keeping with many prescribing guidelines (as discussed above). Extant studies already 
suggest that significant portions of patient samples demonstrate low adherence rates to 
their prescribed regimens on a scheduled basis (Meghani & Bruner, 2013; Meghani & 
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Knafl, 2017; Oldenmenger, Sillevis Smitt, de Raaf, & van der Rijt, 2017). Therefore, we 
must consider potential implications across clinical practice, education, research, and 
policy to promote safe patient outcomes and further understanding the correlates of 
prescribed analgesic taking behaviors.  
Clinical Practice and Education 
There are several potential clinical practice and education implications suggested 
by the findings. First, clinicians might consider exploring and understanding patients’ 
analgesic beliefs throughout the initiation and evaluation of cancer pain treatment plans. 
Although belief clusters did not correlate with adherence outcomes in our study, patient 
beliefs were still significant for patients in thinking about their pain medicines according 
to our MaxDiff utility analysis. Importantly, clinicians should assess for details regarding 
the experiences of cancer pain and pain treatment that inform analgesic beliefs and 
preferences. Clinicians who both prescribe and administer analgesics may develop plans 
for eliciting and considering these experiences in relation to prescribed analgesic 
treatments to better adjust for individual needs. Developing analgesic regimens in 
partnership with patients amid conflicting pain management guidelines provides an 
opportunity to promote patient- and family-centered care. Furthermore, a deeper 
understanding of the patient perspective may improve clinician-patient relationships and 
more transparent dialogue regarding the status of pain and its effective management.  
Second, prescribers must gain a better understanding of what patients believe 
about the strength of opioids being used. While it has been noted that nonopioids and 
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weak opioids cause fewer side effects and should be optimized when possible (WHO, 
1986, 1996), strong opioids continue to be the recommendation of many guidelines for 
moderate to severe cancer pain (NCCN, 2019; Paice et al., 2016; WHO, 2018). 
Understanding potential hesitancies to use opioids from patients and family caregivers 
will likely assist in ensuring pragmatic interventions for pain relief that are acceptable to 
the context of the family and caregiver dynamics.  
Third, patient-based education programs for patients intended to improve pain-
related outcomes have been largely unsuccessful (Oldenmenger et al., 2018). Rather than 
relying solely on education approaches that are still quite heterogenous (e.g., booklets, 
video/computer programs, face-to-face contact), a more dexterous investigation of 
patients’ self-management strategies will aid in identifying problematic analgesic taking 
behaviors and the role of these behaviors on outcomes (Meghani et al., 2019). In addition, 
further attention to systemic, structural, and sociodemographic factors likely influencing 
analgesic use, as noted by findings from chapter 4 above, is vital. In fact, improved focus 
on mitigating side-effects and addressing sociodemographic issues of race, income, and 
health literacy at the structural and systemic level may have more influence in improving 
cancer pain outcomes. Considering these confounders during patients interviews and 
other encounters may facilitate the identification of additional barriers, facilitators, and 





Research and Policy 
First, healthcare workers and advocates must continue to support efforts in 
research and policy that balance societal welfare with individualized pain management 
(Christie et al., 2017; National Academies of Sciences, 2017, 2018). The dissertation 
findings suggest that clinicians must continue to better understand individual beliefs and 
preferences related to analgesic use. At the same time, we must also be cognizant of the 
impacts of the opioid epidemic on the broader population. This is both a delicate balance 
and empirical imperative. In particular, the long-term risks and benefits of analgesic use 
are necessary to explore to ensure an informed patient and clinician population. The high 
prevalence of cancer pain carries an ethical obligation that pain and its associated 
suffering be adequately managed through appropriate care planning and pain burden 
interventions.  
Second, additional qualitative research that provides more subjective data on 
analgesic beliefs and preferences in a time of the opioid epidemic is warranted. While 
there are a number of qualitative studies available that study the phenomenon of 
analgesic adherence for cancer pain (Manzano et al., 2014; Schumacher et al., 2014a, 
2014b), they largely rely on semi-structured interviews. One recent study utilized a 
freelisting method, in addition to interviews, to investigate opioid self-management 
practices for cancer pain patients (Meghani et al., 2020). Methodologies such as concept 
mapping and ethnographic observation (to the extent possible) may provide additional 
insights into the behaviors and contextual dynamics surrounding prescribed analgesic 
taking habits. In particular, approaches that further elicit analgesic beliefs and preferences 
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from different groups based on the experiences of cancer pain and analgesic treatment 
options of patients, families, and prescribers may be helpful in understanding divergent 
priorities among populations. Additional qualitative inquiry may also shed more light on 
patient concerns not measured in this dissertation and provide further information on how 
beliefs interact with systemic/structural and family dynamics to influence analgesic 
taking behaviors and cancer pain outcomes - multifactorial interactions discussed only 
minimally in prior literature (Schumacher et al., 2014a, 2014b). 
Third, further research that explores complementary and integrative health 
approaches to cancer pain management is needed (Bao et al., 2014). Such interventions 
are supported by pain management guidelines (Dowell et al., 2016; NCCN, 2019). 
However, at this time there is insufficient evidence to support their clinical efficacy in 
managing various types of cancer pain (Hetkamp et al., 2019; Kim, Loring, & 
Kwekkeboom, 2018; Kim, Kang, & Lee, 2018; Shin et al., 2016; Wayne et al., 2018). As 
pain outcomes data related to complementary and integrative health services are obtained 
through expanded research initiatives, policies that increase access to, and plan coverage 
and affordability of these services - in conjunction with more traditional analgesic and 
interventional pain relief options - will be imperative to ensure pain care equity across 
patient populations (U.S. Department of Health and Human Services, 2019).   
Finally, continued efforts to clarify the association between patients’ analgesic 
beliefs and analgesic taking behaviors is needed to further personalize care and improve 
safety and health outcomes. While the two analgesic treatment belief clusters were not 
statistically associated with objective adherence behaviors in this dissertation work, there 
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are likely multiple groups of patients that prioritize beliefs in different and nuanced ways, 
which informs their analgesic use accordingly. Further scientific inquiry should assess for 
these additional decision-making patterns. In the end, policies that ensure timely pain 
management for any patient experiencing pain secondary to cancer are needed across 
institutional and system-wide settings.  
Strengths and Limitations 
 
 There are a number of strengths of this dissertation. First, a distinct advantage was 
the use of a rare existing dataset that permitted the measurement of longitudinal and 
objective analgesic and opioid adherence behaviors in the outpatient oncology setting 
(Meghani et al., 2015; Meghani & Knafl, 2017). To our knowledge, this is the only 
dataset that accomplishes these empirics in the United States, with the exception of a 
single recent study that observed a significantly smaller sample (N=17) (Wright et al., 
2019). Second, the sample used was roughly 42% African-American, representing the 
beliefs, demographics, and pain background of an historically underrepresented group. 
Third, the final sample used (N=207) was from T2 and showed no disproportionate 
attrition based on sociodemographic or clinical data from baseline. Last, this dissertation 
is the first to employ MaxDiff analysis in this particular field, making a strong case for 
future use of this approach in healthcare research, particularly in order to better 




 A primary limitation of the empirical portions of the dissertation is the age of the 
data, which was collected between 2009 and 2011. However, it is important to consider 
that this time period aligned with the second wave of the opioid crisis, carrying current 
implications for the ongoing sociopolitical context (CDC, 2018). Second, the sample 
itself was limited to African-American and White patients, excluding the decision-
making utilities of patients from other diverse and minority backgrounds. However, this 
sample met the aims of the parent study, which focused on cancer pain disparities, 
specifically between African-American and White patients. Third, while the beliefs 
evaluated in the MaxDiff questionnaire were based on a well-validated cancer pain 
barriers tool (Ward et al., 1993), this instrument is likely not inclusive of all potentially 
influential beliefs considered when trading-off on decisions regarding analgesic use for 
cancer pain. In addition, while we focused on patient beliefs, the study was not inclusive 
of provider-, family-, or system-level influences associated with analgesic adherence 
behaviors or how those factors may impact patients’ individual beliefs. Further research 
is needed to evaluate a more holistic assessment of beliefs and their association with 
analgesic adherence in the context of these broader interpersonal and structural 
considerations. To date, there are limited data that explore the impact of family and 
caregiver hesitancy on analgesic use as discussed above. Lastly, while our findings are 








 Cancer pain is a debilitating and highly prevalent symptom that impacts patients 
and their families. Analgesics are the cornerstone of cancer pain management and, in 
particular, opioids continue to be foundational for moderate to severe cancer pain 
treatment according to cancer pain guidelines. The phenomenon of analgesic 
nonadherence for cancer pain requires further scholarly dialogue amid this context of the 
opioid crisis but also additional empirical and normative research to elicit its link to and 
validity in improving cancer pain and health outcomes.  
 Our findings suggest that experiential variables rather than analgesic beliefs were 
associated with analgesic adherence in this sample of cancer outpatients. However, the 
field needs more investigation to understand exactly how patients prioritize those beliefs 
in a broader sense, how they trade-off on what is most important to their sense of health 
and well-being, and how the current climate of the opioid crisis, as well as the input of 
family and prescribers, influence those beliefs. Importantly, our research supports 
continued emphasis on systemic and structural influences to understand analgesic taking 
behaviors - such as race, income, and health literacy - as well as further studies that 
describe self-management practices related to prescribed analgesics and opioids. These 
factors must be addressed to ensure pain management equity for all those suffering from 
cancer pain.  
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 Early in the dissertation, we noted that it is impossible to sever the complexities 
of the opioid epidemic from the phenomenon of analgesic nonadherence for cancer pain. 
The opioid epidemic is, indeed, an antecedent of analgesic use for cancer pain. This 
sociopolitical milieu of the evolving opioid crisis is expected to continually shape 
patients’ beliefs, preferences, and values and health providers’ prescribing practices, as 
well as policies that inform opioid access. Future studies should focus on these multi-
level factors and complexities in meaningfully addressing the burden of cancer pain amid 















Bao, Y., Kong, X., Yang, L., Liu, R., Shi, Z., Li, W., . . . Hou, W. (2014). 
Complementary and alternative medicine for cancer pain: an overview of 
systematic reviews. Evidence-Based Complimentary and Alternative Medicine, 
2014, 170396. doi:10.1155/2014/170396 
Bennett, M. I., Bagnall, A. M., & Jose Closs, S. (2009). How effective are patient-based 
educational interventions in the management of cancer pain? Systematic review 
and meta-analysis. Pain, 143(3), 192-199. doi:10.1016/j.pain.2009.01.016 
Centers for Disease Control & Prevention. (2018). Understanding the epidemic. 
Retrieved from https://www.cdc.gov/drugoverdose/epidemic/index.html 
Christie, C., Baker, C., Cooper, R., Kennedy, P. J., Madras, B., & Bondi, P. (2017). The 
President’s commission on combating drug addiction and the opioid crisis. 
Retrieved from https://www.whitehouse.gov/sites/whitehouse.gov/files/images/ 
Final_Report_ Draft_11-1-2017.pdf 
Cohen, J., & Cohen, P. (1983). Applied multiple regression / correlation analysis for the 
behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum Associates. 
Dowell, D., Haegerich, T., & Chou, R. (2019). No shortcuts to safer opioid prescribing. 
New England Journal of Medicine, 380(24), 2285-2287. 
doi:10.1056/NEJMp1904190 
Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC guideline for prescribing opioids 




Hetkamp, M., Bender, J., Rheindorf, N., Kowalski, A., Lindner, M., Knispel, S., . . . 
Teufel, M. (2019). A systematic review of the effect of neurofeedback in cancer 
patients. Integrative Cancer Therapies, 18, 1534735419832361. 
doi:10.1177/1534735419832361 
Jacobsen, R., Samsanaviciene, J., Liubarskiene, Z., Sjøgren, P., Møldrup, C., Christrup, 
L., . . . Hansen, O. B. (2014). Barriers to cancer pain management in Danish and 
Lithuanian patients treated in pain and palliative care units. Pain Management 
Nursing, 15(1), 51-58. doi:http://dx.doi.org/10.1016/j.pmn.2012.06.002 
Johnson, K., Jones, C., Compton, W., Baldwin, G., Fan, J., Mermin, J., & Bennett, J. 
(2018). Federal response to the opioid crisis. Current HIV/AIDS Reports, 15(4), 
293-301. doi:10.1007/s11904-018-0398-8 
Kim, K. S., Loring, S., & Kwekkeboom, K. (2018). Use of art-making intervention for 
pain and quality of life among cancer patients: A systematic review. Journal of 
Holistic Nursing, 36(4), 341-353. doi:10.1177/0898010117726633 
Kim, T. H., Kang, J. W., & Lee, M. S. (2018). Current evidence of acupuncture for 
symptoms related to breast cancer survivors: A PRISMA-compliant systematic 
review of clinical studies in Korea. Medicine (Baltimore), 97(32), e11793. 
doi:10.1097/md. 0000000000011793 
Kroenke, K., Alford, D. P., Argoff, C., Canlas, B., Covington, E., Frank, J. W., . . . 
Sullivan, M. (2019). Challenges with implementing the Centers for Disease 
Control and Prevention Opioid Guideline: A consensus panel report. Pain 
Medicine, 20(4), 724-735. doi:10.1093/pm/pny307 
182 
 
Lamar, A. (2018). S.2680 - The Opioid Crisis Response Act of 2018. Retrieved from 
https://www.congress.gov/bill/115th-congress/senate-bill/2680 
Lee, B. O., Liu, Y., Wang, Y. H., Hsu, H. T., Chen, C. L., Chou, P. L., & Hsu, W. C. 
(2015). Mediating effect of family caregivers' hesitancy to use analgesics on 
homecare cancer patients' analgesic adherence. Journal of Pain and Symptom 
Management, 50(6), 814-821. doi:10.1016/j.jpainsymman.2015.06.014 
Liang, S. Y., Tung, H. H., Wu, S. F., Tsay, S. L., Wang, T. J., Chen, K. P., & Lu, Y. Y. 
(2013). Concerns about pain and prescribed opioids in Taiwanese oncology 
outpatients. Pain Management Nursing, 14(4), 336-342. 
doi:10.1016/j.pmn.2011.08.004 
Manzano, A., Ziegler, L., & Bennett, M. (2014). Exploring interference from analgesia in 
patients with cancer pain: a longitudinal qualitative study. Journal of Clinical 
Nursing, 23(13-14), 1877-1888. doi:10.1111/jocn.12447 
Meghani, S. H., & Bruner, D. W. (2013). A pilot study to identify correlates of 
intentional versus unintentional nonadherence to analgesic treatment for cancer 
pain. Pain Management Nursing, 14(2), e22-30. doi:10.1016/j.pmn.2011.03.003 
Meghani, S. H., Chittams, J., Hanlon, A. L., & Curry, J. (2013). Measuring preferences 
for analgesic treatment for cancer pain: How do African-Americans and Whites 
perform on choice-based conjoint (CBC) analysis experiments? BMC Medical 
Informatics and Decision Making, 13, 118. doi:10.1186/1472-6947-13-118 
Meghani, S. H., Kang, Y., Chittams, J., McMenamin, E., Mao, J. J., & Fudin, J. (2014). 
African Americans with cancer pain are more likely to receive an analgesic with 
183 
 
toxic metabolite despite clinical risks: a mediation analysis study. Journal of 
Clinical Oncology, 32(25), 2773-2779. doi:10.1200/jco.2013.54.7992 
Meghani, S. H., & Knafl, G. J. (2016). Patterns of analgesic adherence predict health care 
utilization among outpatients with cancer pain. Patient Preference and 
Adherence, 10, 81-98. 
doi:10.2147/PPA.S93726Patterns10.2147/PPA.S93726Patient 
Meghani, S. H., & Knafl, G. J. (2017). Salient concerns in using analgesia for cancer pain 
among outpatients: A cluster analysis study. World Journal of Clinical Oncology, 
8(1), 75-85. doi:10.5306/wjco.v8.i1.75 
Meghani, S. H., Thompson, A. M., Chittams, J., Bruner, D. W., & Riegel, B. (2015). 
Adherence to analgesics for cancer pain: A comparative study of African 
Americans and Whites using an electronic monitoring device. Journal of Pain, 
16(9), 825-835. doi:10.1016/j.jpain.2015.05.009 
Meghani, S. H., & Vapiwala, N. (2018). Bridging the critical divide in pain management 
guidelines from the CDC, NCCN, and ASCO for cancer survivors. JAMA 
Oncology, 4(10), 1323-1324. doi:10.1001/jamaoncol.2018.1574 
Meghani, S. H., Wool, J., Davis, J., Yeager, K. A., Mao, J. J., & Barg, F. K. (2020). 
When patients take charge of opioids: Self-management concerns and practices 
among cancer outpatients in the context of opioid crisis. Journal of Pain and 
Symptom Management, 59(3), 618-625. doi:10.1016/j.jpainsymman.2019.10.029 
184 
 
National Academies of Sciences. (2017). Pain management and the opioid epidemic: 
Balancing societal and individual benefits and risks of prescription opioid use. 
Washington, D.C.: National Academies Press. 
National Academies of Sciences. (2018). National Academy of Medicine action 
collaborative on countering the US opioid epidemic.  Retrieved from 
https://nam.edu/programs/action-collaborative-on-countering-the-u-s-opioid-
epidemic/ 
National Academy of Medicine. (2017). First, do no harm: Marshaling clinician 
leadership to counter the opioid epidemic. Washington, D.C.: National 
Academies of Sciences. 
National Comprehensive Cancer Network. (2019). NCCN clinical practice guidelines in 
oncology: Adult cancer pain V1.2019-January 25, 2019. Retrieved from 
https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf 
Oldenmenger, W. H., Geerling, J. I., Mostovaya, I., Vissers, K. C. P., de Graeff, A., 
Reyners, A. K. L., & van der Linden, Y. M. (2018). A systematic review of the 
effectiveness of patient-based educational interventions to improve cancer-related 
pain. Cancer Treatment Reviews, 63, 96-103. doi:10.1016/j.ctrv.2017.12.005 
Oldenmenger, W. H., Sillevis Smitt, P. A., van Dooren, S., Stoter, G., & van der Rijt, C. 
C. (2009). A systematic review on barriers hindering adequate cancer pain 
management and interventions to reduce them: a critical appraisal. European 
Journal of Cancer, 45(8), 1370-1380. doi:10.1016/j.ejca.2009.01.007 
185 
 
Oldenmenger, W. H., Sillevis Smitt, P. A. E., de Raaf, P. J., & van der Rijt, C. C. D. 
(2017). Adherence to analgesics in oncology outpatients: Focus on taking 
analgesics on time. Pain Practice, 17(5), 616-624. doi:10.1111/papr.12490 
Paice, J. A., Portenoy, R., Lacchetti, C., Campbell, T., Cheville, A., Citron, M., . . . 
Bruera, E. (2016). Management of chronic pain in survivors of adult cancers: 
American Society of Clinical Oncology clinical practice guideline. Journal of 
Clinical Oncology, 34(27), 3325-3345. doi:10.1200/JCO.2016.68.5206 
Ranapurwala, S. I., Naumann, R. B., Austin, A. E., Dasgupta, N., & Marshall, S. W. 
(2019). Methodologic limitations of prescription opioid safety research and 
recommendations for improving the evidence base. Pharmacoepidemiology and 
Drug Safety, 28(1), 4-12. doi:10.1002/pds.4564 
Rau, K. M., Chen, J. S., Wu, H. B., Lin, S. F., Huang, M. L., Tai, C. J., . . . Kuen Hsieh, 
R. (2017). Cancer-related pain: a nationwide survey of patients' treatment 
modification and satisfaction in Taiwan. Japanese Journal of Clinical Oncology, 
47(11), 1060-1065. doi:10.1093/jjco/hyx124 
Rhee, Y. O., Kim, E., & Kim, B. (2012). Assessment of pain and analgesic use in African 
American cancer patients: factors related to adherence to analgesics. Journal of 
Immigrant and Minority health, 14(6), 1045-1051. doi:10.1007/s10903-012-9582-
x 
Rosa, W. E., Chittams, J., Riegel, B., Ulrich, C. M., & Meghani, S. H. (2019). Patient 
decision-making trade-offs related to analgesic use for cancer pain: A MaxDiff 
186 
 
analysis study. Pain Management Nursing. Epub ahead of print. 
doi:10.1016/j.pmn. 2019.07.013 
Rosa, W. E., Riegel, B., Ulrich, C. M., & Meghani, S. H. (2020). A concept analysis of 
analgesic nonadherence for cancer pain in a time of opioid crisis. Nursing 
Outlook, 68(1), 83-93. doi:10.1016/j.outlook.2019.06.017 
Schumacher, K. L., Plano Clark, V. L., West, C. M., Dodd, M. J., Rabow, M. W., & 
Miaskowski, C. (2014a). Pain medication management processes used by 
oncology outpatients and family caregivers part I: health systems contexts. 
Journal of Pain and Symptom Management, 48(5), 770-783. 
doi:10.1016/j.jpainsymman.2013.12.242 
Schumacher, K. L., Plano Clark, V. L., West, C. M., Dodd, M. J., Rabow, M. W., & 
Miaskowski, C. (2014b). Pain medication management processes used by 
oncology outpatients and family caregivers part II: home and lifestyle contexts. 
Journal of Pain and Symptom Management, 48(5), 784-796. 
doi:10.1016/j.jpainsymman.2013.12.247 
Shi, Q., Smith, T. G., Michonski, J. D., Stein, K. D., Kaw, C., & Cleeland, C. S. (2011). 
Symptom burden in cancer survivors 1 year after diagnosis: A report from the 
American Cancer Society’s studies of cancer survivors. Cancer, 117(12), 2779-
2790. doi:10.1002/cncr.26146 
Shin, E. S., Seo, K. H., Lee, S. H., Jang, J. E., Jung, Y. M., Kim, M. J., & Yeon, J. Y. 
(2016). Massage with or without aromatherapy for symptom relief in people with 
187 
 
cancer. Cochrane Database Syst Reviews, (6), Cd009873. 
doi:10.1002/14651858.CD009873. pub3 
Simone, C. B., 2nd, Vapiwala, N., Hampshire, M. K., & Metz, J. M. (2012). Cancer 
patient attitudes toward analgesic usage and pain intervention. Clinical Journal of 
Pain, 28(2), 157-162. doi:10.1097/AJP.0b013e318223be30 
Thurstone, L. (1927). A law of comparative judgment. Psychological Review, 34, 278-
286. doi:10.1037/h0070288 
Torresan, M. M., Garrino, L., Borraccino, A., Macchi, G., De Luca, A., & Dimonte, V. 
(2015). Adherence to treatment in patient with severe cancer pain: A qualitative 
enquiry through illness narratives. European Journal of Oncology Nursing, 19(4), 
397-404. doi:10.1016/j.ejon.2015.01.001 
U.S. Department of Health and Human Services. (2019). Pain management best practices 
inter-agency task force report: Updates, gaps, inconsistencies, and 
recommendations. Retrieved from https://www.hhs.gov/ash/advisory-
committees/pain/reports/index.html 
Valeberg, B. T., Miaskowski, C., Paul, S. M., & Rustoen, T. (2016). Comparison of 
oncology patients' and their family caregivers' attitudes and concerns toward pain 
and pain management. Cancer Nursing, 39(4), 328-334. 
doi:10.1097/ncc.0000000000000319 
van den Beuken-van Everdingen, M. H., Hochstenbach, L. M., Joosten, E. A., Tjan-
Heijnen, V. C., & Janssen, D. J. (2016). Update on prevalence of pain in patients 
188 
 
with cancer: systematic review and meta-analysis. Journal of Pain and Symptom 
Management, 51(6), 1070-1090 e1079. doi:10.1016/j.jpainsymman.2015.12.340 
Walker, L. O., & Avant, K. C. (2019). Strategies for theory construction in nursing (6th 
ed.). New York, NY: Pearson. 
Ward, S. E., Goldberg, N., Miller-McCauley, V., Mueller, C., Nolan, A., Pawlik-Plank, 
D., . . . Weissman, D. E. (1993). Patient-related barriers to management of cancer 
pain. Pain, 52(3), 319-324.  
Wayne, P. M., Lee, M. S., Novakowski, J., Osypiuk, K., Ligibel, J., Carlson, L. E., & 
Song, R. (2018). Tai Chi and Qigong for cancer-related symptoms and quality of 
life: a systematic review and meta-analysis. Journal of Cancer Survivors, 12(2), 
256-267. doi:10.1007/s11764-017-0665-5 
World Health Organization. (1986). Cancer pain relief. Geneva, Switzerland: World 
Health Organization. 
World Health Organization. (1996). Cancer pain relief and palliative care. Geneva, 
Switzerland: World Health Organization.  
World Health Organization. (2018). WHO Guidelines for pharmacological and 
radiotherapeutic management of cancer pain in adults and adolescents. Geneva, 
Switzerland: World Health Organization. 
Wright, E. M., El-Jawahri, A., Temel, J. S., Carr, A., Safren, S. A., Park, E. R., . . . 
Traeger, L. (2019). Patient patterns and perspectives on using opioid regimens for 




Yeager, K. A., Williams, B., Bai, J., Cooper, H. L. F., Quest, T., Meghani, S. H., & 
Bruner, D. W. (2019). Factors related to adherence to opioids in black patients 
with cancer pain. Journal of Pain and Symptom Management, 57(1), 28-36. 
doi:10.1016/j.jpainsymman. 2018.10.491 
 
